

## AAACE Clinical Guidance

# American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update



Karl Nadolsky, DO, FACE, DABOM<sup>1</sup>, W. Timothy Garvey, MD, MACE<sup>2</sup>,  
Monica Agarwal, MD, MEHP, FACE, DABOM<sup>2</sup>, Alex Bonnacaze, MD<sup>3</sup>,  
Bartolome Burguera, MD, PhD<sup>4</sup>, Michelle DeGeeter Chaplin, PharmD<sup>5</sup>,  
Marcio L. Griebeler, MD, FACP, DABOM<sup>4</sup>, Samantha R. Harris, MD, DABOM<sup>6</sup>,  
Jeffrey N. Schellinger, MCN, RD<sup>7</sup>, Juliana Simonetti, MD, DABOM<sup>8</sup>,  
Reshmi Srinath, MD, DABOM<sup>9</sup>, Volkan Yumuk, MD, FACE<sup>10</sup>

<sup>1</sup> Michigan State University College of Human Medicine, East Lansing, Michigan

<sup>2</sup> University of Alabama at Birmingham, Birmingham, Alabama

<sup>3</sup> Pinehurst Medical Clinic, Pinehurst, North Carolina

<sup>4</sup> Cleveland Clinic, Cleveland, Ohio

<sup>5</sup> Appalachian Mountain Health, Asheville, North Carolina

<sup>6</sup> Scripps Clinic, San Diego, California

<sup>7</sup> UT Southwestern Medical Center, Dallas, Texas

<sup>8</sup> University of Utah Health, Salt Lake City, Utah

<sup>9</sup> Icahn School of Medicine at Mount Sinai, New York, New York

<sup>10</sup> Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Turkey

## ARTICLE INFO

## Article history:

Received 10 June 2025

Received in revised form

23 July 2025

Accepted 23 July 2025

Available online 16 September 2025

## Key words:

ABCD

adiposity-based chronic disease

complication-centric

complications

**Objective:** This 2025 consensus statement provides evidence-based visual guidance in graphic algorithms and a summary of evidence to assist health care professionals and adults with obesity and adiposity-based chronic disease (ABCD) in shared decision making to improve care and achieve health goals.

**Methods:** AAACE selected a task force of medical experts to update the 2016 AAACE algorithm for the medical care of patients with obesity and align this algorithm update with related AAACE clinical guidance. Details on surgical and procedural therapies for obesity treatment as well as the care of pediatric-aged patients are beyond the scope of this algorithm.

**Results:** The algorithm includes 11 sections: (1) principles of person-centered and complication-centric management of obesity/ABCD, (2) care model for people with obesity/ABCD: screening and diagnosis, (3) diagnosis: anthropometric component, (4) diagnosis: clinical component, (5) individualized treatment plan, therapeutic goals, and follow-up, (6) response to therapy and weight-loss targets for people with ABCD, (7) behavioral/lifestyle therapy for people with obesity/ABCD, (8)

**Abbreviations:** AAACE, American Association of Clinical Endocrinology; ABCD, adiposity-based chronic disease; A1C, hemoglobin A1c; BBS, Bardet-Biedl Syndrome; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcome trial; DXA, dual-energy x-ray absorptiometry; ER, extended release; FDA, U.S. Food and Drug Administration; GLP-1 RA, glucagon-like peptide-1 receptor agonist; GIP/GLP-1 RA, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; IWB, internalized weight bias; MACE, major adverse cardiovascular events; MC4R, melanocortin 4 receptor; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; MRI, magnetic resonance imaging; ORCD, obesity-related complications and diseases; PCOS, polycystic ovary syndrome; POMC, proopiomelanocortin; OA, osteoarthritis; OSA, obstructive sleep apnea; SC, subcutaneous; T2D, type 2 diabetes; WC, waist circumference.

Address correspondence to the American Association of Clinical Endocrinology, 7643 Gate Parkway, Suite 104-328, Jacksonville, FL 32256.

Email address: [guidelines@aaace.com](mailto:guidelines@aaace.com)

**Disclaimer:** This document represents the official position of the American Association of Clinical Endocrinology on the subject matter at the time of publication. Subject matter experts who participated on the task force used their judgment and experience supported by relevant scientific evidence as available. Every effort was made to achieve consensus among the task force members. Consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. We encourage health care professionals to use this information in conjunction with their best clinical judgment. The presented guidance may not be appropriate in all situations. Any decision(s) by health care professionals to apply this guidance provided in this consensus statement must be made in consideration of local resources and individual patient circumstances.

<https://doi.org/10.1016/j.eprac.2025.07.017>

1530-891X/© 2025 AAACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

obesity  
obesity algorithm  
obesity management  
obesity medications

hierarchies of preferred medications for complication-centric care of people with ABCD, (9) lower-cost pharmacologic step therapy for ABCD, (10) medications for obesity: individualization of therapy, and (11) medications for obesity approved by the U.S. Food and Drug Administration.

**Conclusions:** This 2025 algorithm for the medical care of adults with obesity underscores that ABCD is a complex, chronic disease that necessitates long-term treatment and care. Emphasis is placed on optimizing health rather than just weight reduction and achieving clinical goals other than a singular focus on body mass index (ie, complication-centric care). Choice of interventions and intensity of treatment should be individualized, taking disease severity or stage into account. Equality of care and reducing weight bias and stigma through a biopsychosocial chronic care model are critical and included throughout this clinical guidance statement.

© 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

## Introduction


The first AACE consensus statement on the management of obesity was published in 1997,<sup>1</sup> followed by position statements in 1998,<sup>2</sup> 2012,<sup>3</sup> and 2014<sup>4</sup> (for a new diagnosis of obesity as a chronic disease). In 2016, AACE published a guideline and algorithm for the comprehensive care of patients with obesity which were designed within the context of a chronic care model and diagnostic framework to align with the definition and pathophysiology of obesity as a chronic disease.<sup>5</sup> This was the first evidence-based obesity guideline to explicitly advocate a complication-centric approach to care. The 2016 clinical guidance supported mode and intensity of therapy to match disease severity based on complications and not on body mass index (BMI), emphasizing that BMI conveys no direct information regarding the impact of excess adiposity on an individual's health.<sup>4,5</sup> The 2016 guideline and algorithm added staging of obesity based on the risk, presence, and clinical severity of complications as the clinical component of the diagnosis. Anthropometric and clinical evaluations are then used to stage the severity of the disease which can guide goals and intensity of the complication-centric treatment plan.<sup>6–8</sup> In 2017, AACE published a position statement that proposed a diagnostic term to explicitly identify obesity as a chronic disease: adiposity-based chronic disease (ABCD).<sup>9</sup> The European Association for the Study of Obesity followed suit in 2019 with a position statement endorsing ABCD as a diagnostic term in line with their previous proposal to improve the *International Classification of Diseases* diagnostic criteria beyond BMI.<sup>10</sup>

ABCD refers to what is being treated (neurohormonal-driven dysregulation of energy balance leading to abnormalities in the mass, distribution, and function of adipose) and why the disease is treated (a chronic disease with complications that impair quality of life and confer morbidity and mortality). This diagnosis goes beyond that of obesity based on BMI. The international Lancet Commission on Obesity recently developed definitions of “preclinical” obesity to indicate a state of excess adiposity without obesity-related diseases or complications and “clinical” obesity to convey the presence of complications, defined as alterations in organ structure and/or function usually producing symptoms that arise because of the presence of excess adiposity per se.<sup>11</sup> The Lancet Commission regards obesity-related diseases as entities that are more common in obesity and share pathophysiological processes but require an additional pathophysiological contribution unrelated to the presence of excess adiposity. AACE views ABCD as an umbrella term that encompasses all aspects of the disease, from risk factors requiring primary prevention of obesity, to preclinical and clinical obesity, and all obesity-related complications and diseases (ORCD). [Figure 1](#) shows the interrelationships between terms used by the Lancet

Commission and the AACE obesity algorithm and the comprehensive nature of ABCD as a diagnostic term that comprises all aspects of the disease. Evidence-based interventions should be considered and available over the spectrum of ABCD—including obesity prevention, treatment of stage 1 obesity, and in people with stage 2 or 3 disease and ORCD—when needed to improve health. Operational definitions for the AACE algorithm update are contained in [Box A](#).

Obesity is a neurohormonal metabolic disease that is chronic and heterogeneous.<sup>11</sup> The unifying phenotypic feature of obesity is excess or abnormally distributed adipose tissue with the potential to impair health.<sup>12–15</sup> The physiology of energy homeostasis involves the coordinated interaction of multiple neuroendocrine satiety factors arising peripherally and acting on feeding centers in the brain.<sup>15</sup> Obesity results from an interplay between complex genetic and environmental factors that produce dysregulated energy homeostasis involving these satiety factors and central neuroregulation, resulting in excess accumulation of adipose tissue.<sup>16–19</sup> Dysregulated secretion of satiety factors and their actions in the hypothalamus, brain stem, mesolimbic system, and other centers generate and sustain a state of excess adiposity. Observations are consistent with the model that the body defends its fat mass (fuel stores) around an equilibrium based on interactions involving genetics, behavior, biological factors, and our current obesogenic environment.<sup>19</sup> Thus, body fat is biologically defended, which explains why weight regain frequently occurs after achieving weight reduction by behavioral efforts alone.<sup>20–22</sup> With the exception of orlistat and cellulose hydrogels, all other obesity medications target these central mechanisms that generate excess adiposity and the maladaptive responses driving weight regain after weight loss.<sup>23</sup>

With the addition of newer second-generation obesity medications and their enhanced ability to optimize the health of people with ABCD by preventing and treating complications, this 2025 AACE algorithm for the evaluation and treatment of adults with obesity/ABCD builds on the 2016 AACE obesity algorithm.<sup>5</sup> This algorithm update expands on the Lancet Commission staging framework for obesity<sup>11</sup> and aligns with the international joint consensus statement on obesity stigma,<sup>24</sup> the European Association for the Study of Obesity new framework for the diagnosis, staging, and management of obesity,<sup>25</sup> and the AACE consensus statement on internalized weight bias, stigma, and mental health<sup>26</sup> as key components of obesity care. Furthermore, the algorithm for the first time establishes hierarchies of preferred medications for the complication-centric care of people with specific ORCD based on clinical trial evidence for the amelioration of specified cardiometabolic and biomechanical outcomes.<sup>27</sup> As in the 2023 AACE type 2 diabetes algorithm and 2023 AACE consensus statement on obesity



**Fig. 1.** Adiposity-based chronic disease and relationships involving the AACE obesity algorithm and terms used by the Lancet Commission on Obesity. *MASH* = metabolic dysfunction-associated steatohepatitis.

stigma,<sup>26,28</sup> this consensus statement on treatment of those with ABCD centers on the principles of individualized and whole-person health while de-emphasizing weight reduction alone.<sup>9,26</sup>

The first algorithm (Algorithm 1) includes 9 principles developed by uniform consensus for person-centered care of adults with obesity/ABCD. These principles constitute optimal care for people with ABCD. Conversely, management plans that do not

feature one or more of these principles are considered suboptimal in the care of these individuals.

The principles in Algorithm 1 direct a care model for people with ABCD consistent with the overall AACE obesity algorithm. Essential to person-centered care of those with ABCD is a thorough diagnostic evaluation followed by the development and implementation of a personalized treatment plan with individualized health goals that consider weight

**Box A**

**Definitions of Terms**

**Obesity** is a state of excessive adiposity with or without abnormal distribution or function of adipose tissue.

**Adiposity-based chronic disease (ABCD)** is a diagnostic term that signifies a heterogeneous, progressive, chronic disease that arises due to abnormal neuroendocrine control of energy balance and caloric intake leading to excess or abnormal adiposity, which can give rise to obesity-related complications and diseases (ORCD) that confer morbidity and mortality and/or impair quality of life. ABCD encompasses primary risk factors, disease pathophysiology together with prevention and treatment at the primordial, primary, secondary, and tertiary phases of progression, and includes all disease stages (1, 2, and 3) based on the presence and severity of obesity-related complications and diseases. Treatment is required at all stages to prevent, ameliorate, or reverse obesity-related complications and diseases.

**Obesity-related complications and diseases (ORCD)** is a term used in this algorithm to include both obesity complications and obesity-related diseases as defined below. The presence of ORCD warrants designation of ABCD as stage 2 (if mild to moderate) or stage 3 (if severe). AACE prefers this umbrella term because treatment can be warranted and effective irrespective of the pathophysiological differentiation between complications and related diseases.

**Obesity complications\*** are the clinical consequences caused by progressive organ dysfunction or end-organ damage induced by excess adiposity. These complications arise due to structural and/or functional changes in tissues or organs, often producing symptoms, and are integrally related to effects of excess adiposity. The presence of complications warrants AACE staging as 2 or 3 ABCD based on severity.

**Obesity-related diseases\*** meet 3 criteria: (1) they are commonly associated with obesity and/or more prevalent in people with obesity than in the general population, (2) they are pathophysiologic processes in obesity that contribute to overall pathogenesis, and (3) they involve the contribution of a pathophysiological process unrelated to obesity per se (eg, type 2 diabetes, which requires an insulin secretory defect, or certain forms of cancer that may require the expression of an oncogene). The presence of obesity-related diseases warrants AACE staging as 2 or 3 ABCD based on severity.

**Comorbidities\*** represent diseases or conditions that incidentally coexist with obesity but are not caused or facilitated by obesity.

**Preclinical obesity\*** is the state of obesity without any ORCD. These patients are at risk of complications and exist within the spectrum of ABCD as disease stage 1, which requires treatment to prevent ORCD.

**Clinical obesity\*** applies to patients who have developed demonstrable or symptomatic complications as defined above. Note that while the distinction between ORCD is relevant to pathophysiology, AACE does not make this distinction in the clinical staging of ABCD (stage 2 or 3) because both can be treated effectively via weight-loss therapy.

\* The authors view these definitions as consistent with those advanced by the 2025 Lancet Commission on Obesity.<sup>11</sup>

PRINCIPLES OF PERSON-CENTERED AND COMPLICATION-CENTRIC MANAGEMENT OF OBESITY/ABCD

|    |                                                                                                                                                                                                                                                                                                                                           |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Emphasize whole-person health and de-emphasize BMI and weight-centric approaches in the treatment of individuals with obesity/ABCD.                                                                                                                                                                                                       |
| 2. | People with obesity/ABCD should be evaluated by an empathetic trained health care professional to include both the anthropometric and clinical components of the diagnosis and should be followed long-term by a health care professional who will manage weight loss and assure that treatment goals for optimizing health are achieved. |
| 3. | For the anthropometric component of the diagnosis, obesity is evaluated using BMI with clinical confirmation of excess adiposity, waist circumference, waist-to-height ratio, and assessment of body composition when clinically needed.                                                                                                  |
| 4. | For the clinical component of the diagnosis and disease staging of ABCD, assess the risk, presence, and severity of ORCD. Include internalized weight bias and impact of stigmatization as part of clinical staging.                                                                                                                      |
| 5. | Involve the individual in shared decision-making to determine personalized health goals while targeting sufficient weight loss to achieve clinical treatment goals for health.                                                                                                                                                            |
| 6. | Develop treatment plans involving lifestyle, pharmacologic, and surgical options using an individualized approach that considers complications and their severity, patient preferences, social determinants of health, psychological disorders, and access to care.                                                                       |
| 7. | The goals of therapy are to improve health and the quality of life by preventing or treating ORCD, not solely defined by the loss of a specific amount of weight.                                                                                                                                                                         |
| 8. | Therapy, beyond behavioral/lifestyle alone, should be considered at all stages of ABCD (stages 1, 2, or 3) when needed to improve the health of patients.                                                                                                                                                                                 |
| 9. | Implement a plan for long-term follow-up with each patient to monitor maintenance of healthy goals, clinical outcomes, and treatment modifications as needed.                                                                                                                                                                             |

Abbreviations: ABCD, adiposity-based chronic disease; BMI, body mass index; ORCD, obesity-related complications and diseases

Algorithm Figure 1 - Guiding Principles  
COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.



Algorithm 1. Principles of person-centered and complication-centric management of obesity/adiposity-based chronic disease.

reduction in the context of prevention, mitigation, and treatment of ORCD. Care should be delivered in an empathetic and culturally sensitive manner, and social determinants of health should be considered in the development of an individualized care plan. Algorithms 2 through 5 show the complication-centric care model and include: (1) screening and diagnosis involving both anthropometric and clinical components, which necessitates clinical evaluation and basic laboratory testing (Algorithm 2); (2) criteria for the anthropometric component of the diagnosis using ethnic-specific cutoffs for BMI and adipose distribution (Algorithm 3); (3) the clinical component of the diagnosis and the staging of clinical severity based upon ABCD ORCD (Algorithm 4); and (4) the use of disease staging in developing and implementing an individualized holistic treatment plan, establishing the clinical goals of therapy through shared decision making, and following up with appropriate treatment modifications based upon both the clinical response to therapy and a longer-term strategy for health maintenance (Algorithm 5).

The diagnosis of ABCD involves both an anthropometric component to assess adiposity and a clinical component to


determine disease severity and the impact of adiposity on health and quality of life.

*Anthropometric Component*

BMI is appropriate for screening; however, excess adiposity must be confirmed by inspection and physical examination. Assess the mass and distribution of body fat using BMI and waist-to-height ratio. The measurement of waist-to-height ratio involves the measurement of waist circumference (WC), and BMI and WC should be interpreted considering age, sex, and ethnicity. Additional modalities such as dual-energy x-ray absorptiometry (DXA) or impedance plethysmography may be used to assess body composition and/or distribution of adipose tissue when the anthropometric measurements and examination are discordant or do not match the clinical findings. BMI measurements should be interpreted clinically, taking into account muscle mass, edema, soft tissue masses, and any contributions to body weight other than adipose tissue. Special consideration should be given to the presence of sarcopenia and sarcopenic obesity in patients who are at risk.



## CARE MODEL FOR PEOPLE WITH OBESITY/ABCD: SCREENING AND DIAGNOSIS



Abbreviations: **ABCD**, adiposity-based chronic disease; **BMI**, body mass index; **ORCD**, obesity-related complications and diseases

#### Algorithm Figure 2 - Screening and Diagnosis

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



**Algorithm 2.** Care model for people with obesity/adiposity-based chronic disease: screening and diagnosis.

### Clinical Component

Stage the clinical severity of ABCD based on risk, presence, and severity of ORCD. Staging requires a thorough weight and medical history, review of systems, physical examination, key biochemical data, and possibly imaging or other diagnostic testing. Clinical evaluation should include an assessment for potential monogenic or syndromic causes, weight-gain promoting medications, endocrinopathies, psychosocial factors, and/or other potential contributors.

### Screening and Assessment


As indicated in the care model (Algorithm 2), the anthropometric component of diagnosis begins with screening using BMI (Algorithm 3). A physical examination is needed, however, to confirm the presence of excess adiposity. As BMI does not inform about the distribution of adiposity, WC and waist-to-height ratio are assessed as indicators of central body adiposity which reflects

cardiometabolic health. The assessment of adipose tissue mass and distribution and body composition may require additional methodologies beyond a physical examination. Assessment of body composition using DXA scanning, bioelectric impedance, 3-dimensional photoimaging, or magnetic resonance imaging (MRI) should be used to refine measurements of adipose tissue mass and distribution when needed. DXA or MRI can be used to assess lean body mass or muscle volume and bone mass/mineral density in people who are at high risk or who are experiencing symptoms or outcomes of sarcopenia and osteopenia.

### BMI

After physical confirmation of excess adiposity, use BMI to classify individuals into categories of overweight (BMI 25.0-29.9 kg/m<sup>2</sup>), class I obesity (BMI ≥30.0-34.9 kg/m<sup>2</sup>), class II obesity (BMI ≥35.0-39.9 kg/m<sup>2</sup>), or class III obesity (BMI ≥40.0 kg/m<sup>2</sup>). These cutoffs are generally recommended by the World Health Organization<sup>29</sup> and are operative in North and South America,

DIAGNOSIS: ANTHROPOMETRIC COMPONENT



Abbreviations: BMI, body mass index; DXA, dual-energy X-ray absorptiometry; WHO, World Health Organization

Algorithm Figure 3 – Diagnosis: Anthropometric Component

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.




Algorithm 3. Diagnosis: anthropometric component.


Europe, sub-Saharan Africa, the Middle East, and Australia. In the Asia-Pacific region, lower cutoff values for overweight and obesity are recognized because of the greater health risk at lower levels of BMI in these populations.<sup>30–34</sup> For example, in India,<sup>30</sup> South Korea,<sup>35</sup> and Japan,<sup>36</sup> a cutoff point of ≥25.0 kg/m<sup>2</sup> is indicative of obesity and 23.0 kg/m<sup>2</sup> to 24.9 kg/m<sup>2</sup> is the range for overweight. In China, BMI ≥28.0 kg/m<sup>2</sup> represents obesity and 24.0 kg/m<sup>2</sup> to 27.9 kg/m<sup>2</sup> overweight.<sup>37</sup> Other research suggests that these cutoff values may need to be modified for individuals from Asian-Pacific regions who have been living in Western societies.<sup>31</sup> In South and Central American adults, a cutoff for obesity of 27.2 kg/m<sup>2</sup> has been recommended in older adults.<sup>38</sup> In any case, clinical interpretation of BMI includes the need to confirm that elevated BMI values represent excess adiposity after considering an individual's age, sex, muscularity, fluid status (hydration, edema, third space fluid collection), and the presence of sarcopenia (sarcopenic obesity can refer to people with low BMI but presence of adiposity) and osteopenia in those who are at risk.<sup>5,11,14,39,40</sup> It is important to consider that BMI may underestimate adiposity and risk among frail or elderly individuals and overestimate adiposity in muscular athletes.

WC and Waist-to-Height Ratio

WC and waist-to-height ratio are valuable and practical measurements for evaluating the distribution of adipose tissue.<sup>41,42</sup> In the United States and Canada, WC cutoff values of ≥102 cm (≥40 in) in men and ≥88 cm (≥34.5 in) in women have been suggested to indicate increased cardiometabolic risk. In Europe, sub-Saharan African, and the Middle East, the recommended cutoffs are ≥94 cm (≥37 in) in men and ≥80 cm (≥31.5 in) in women, and in East and South Asia and South and Central America, these cutoffs are generally considered to be ≥90 cm (≥35 in) in men and ≥80 cm (≥31.5 in) in women as indicative of abdominal obesity. Evidence indicates that waist-to-height ratio is a superior indicator of cardiovascular disease (CVD) risk compared with WC.<sup>33</sup> The waist-to-height threshold value of ≥0.5 is indicative of increased risk in both males and females and across ethnic populations, and has been advocated by professional societies and various organizations.<sup>25,33,43</sup> Additional measurements of adiposity, such as bioelectric impedance, air/water displacement plethysmography, 3-dimensional imaging, or DXA, may be useful if BMI and physical examination results are equivocal, inconclusive, or require further



## INDIVIDUALIZED TREATMENT PLAN, THERAPEUTIC GOALS, AND FOLLOW-UP



<sup>a</sup> The degree of severity for ORCD is based on clinical judgment, incorporating findings from physical examination, laboratory testing, and/or other diagnostic procedures, as well as a person's symptomatology, in ways that apply to each individual complication.

Abbreviations: ABCD, adiposity-based chronic disease; ORCD, obesity-related complications and diseases

Algorithm Figure 5 – Treatment Plan, Therapeutic Goals, and Follow-Up

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.



Algorithm 5. Individualized treatment plan, therapeutic goals, and follow-up.

complications that define clinical obesity<sup>56</sup> as well as an increased risk of obesity-related diseases such as type 2 diabetes (T2D) and obesity-related cancers (eg, colon, esophageal, thyroid, myeloma, non-Hodgkin lymphoma, endometrial, and postmenopausal breast cancers).<sup>57</sup> AACE regards stage 1 or preclinical obesity as part of the spectrum of ABCD (Fig. 1).

Clinical staging systems have shown superiority in predicting health outcomes, including mortality, to a greater degree than anthropometric measures alone.<sup>6,8,9,58-63</sup> The AACE staging system for ABCD assesses the presence and severity of multiple key ORCD that can be prevented or treated via weight loss (Fig. 2) including hypertension (HTN), dyslipidemia, dysglycemia from prediabetes and risk of T2D, overt diabetes, obstructive sleep apnea (OSA),<sup>64</sup> metabolic dysfunction–associated steatotic liver disease (MASLD), polycystic ovary syndrome (PCOS), osteoarthritis (OA),<sup>65</sup> atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and many others.<sup>5</sup> The degree of severity for these complications is based on clinical judgment, incorporating findings from the physical examination, laboratory testing, and/or other diagnostic procedures, as well as a person's symptomatology, in ways that apply to each individual complication.

### Clinical Evaluation

People with ABCD should be seen by a trained health care professional who conducts a clinical evaluation with an orientation to complication-centric care, and with the capability to assure long-term care either personally or through referral. As shown in Algorithm 4 and Figure 3, the evaluation should include a medical and weight-related history that considers previous attempts to lose weight and involves a physical examination, an ABCD-focused review of systems, a family and social history, a review of medications, and laboratory testing as indicated to screen for ORCD. Laboratory tests specifically recommended for assessing cardiometabolic risk include serum creatinine (for estimated glomerular filtration rate), lipid panel, fasting blood glucose, hemoglobin A1c (A1C), and aspartate aminotransferase, alanine aminotransferase, and platelet count (for calculation of fibrosis-4).<sup>66-69</sup> Other laboratory tests can be obtained to assess general health, including complete blood cell count, electrolytes/comprehensive metabolic panel, electrocardiogram, and urine analysis. Further testing may be needed, only when clinically indicated, based upon history, examination, review of systems, and initial laboratory results to assess the presence and severity of specific ORCD (eg, oral glucose tolerance

**Table 1**  
Staging of Adiposity-Based Chronic Disease and the Incorporation of Bias and Stigmatization, Psychological Health, and Social Determinants of Health in the Assessment of Disease Severity and Individualized Care Plans

| Stage No. | Description                                                                                                                                                                                                                 | Across All Stages                                                                                                                                                                                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1         | No known obesity-related cardiometabolic, biomechanical, or other psychological disease. Associated with increased risk of developing obesity complications and related diseases which may be mitigated by weight reduction | Internalized weight bias and stigmatization, psychological conditions, and social determinants of health should be assessed in all stages for the degree to which they impact quality of life or treatment and incorporated into individualized care plans |
| 2         | 1 or more mild to moderate obesity-related diseases                                                                                                                                                                         |                                                                                                                                                                                                                                                            |
| 3         | At least 1 severe, or multiple, obesity-related disease and/or complications                                                                                                                                                |                                                                                                                                                                                                                                                            |

Adapted from Garvey et al<sup>5</sup> and Nadolsky et al.<sup>26</sup>

testing,<sup>70</sup> thyroid-stimulating hormone, apolipoprotein B-100, cortisol, knee radiographs, hepatic elastography, polysomnography, or genetic testing as well as psychology, sociology, or nutrition referrals).

Figure 2 lists examples of ORCD that may potentially be identified in the course of the clinical evaluation of people with ABCD. AACE stage 2 (mild-moderate) and stage 3 (severe) are equally applicable to both obesity-related diseases and obesity complications as defined by the Lancet Commission on Obesity (see definitions in Box A). While this differentiation is of conceptual and pathophysiological interest, operationally this does not have practical import in the AACE obesity algorithm, since both ORCD can warrant weight-loss therapy based on the stage of severity. People with stage 1 obesity also merit treatment based on clinical judgment and the risk of disease progression. Therapy, beyond behavioral/lifestyle alone, should be considered at all stages of ABCD when needed to improve patient health, including treatment of stage 1 obesity, and in people with stage 2 or 3 disease.

In Figure 2, ABCD stages 2 and 3 in the AACE obesity algorithm do not differentiate between ORCD, since both complications and

diseases can be ameliorated by weight-loss therapy. Also note that the distinction between ORCD as defined by the Lancet Commission can become blurred, and complications may be considered to be more consistent with related diseases and vice versa in some individuals depending on the pathophysiological contributions of obesity.

*Personalized Therapeutic Care Plan*

The development of an individualized care plan begins with the staging of ABCD. The modality and intensity of interventions should be proportional to the clinical stage of ABCD, reflecting the risk, presence, and severity of ORCD. Select the modality and intensity of treatment based on the degree of weight loss and/or other beneficial aspects of treatment needed to prevent or ameliorate specific ORCD. Interventions may be adjusted if there is insufficient weight loss to achieve targets for improvement in quality of life and adequate resolution of ORCD impairing health and conferring morbidity and mortality.

Each patient should be engaged in developing a personalized care plan. Each person’s values, preferences, and access to care

Examples of ORCD that May Be Detected in the Clinical Evaluation of ABCD

| ABCD Stage 1                                   | ABCD Stage 2 or 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No ORCD identified following intake evaluation | <b>Obesity Complications*</b> <ul style="list-style-type: none"><li>• OA (knee, hip)</li><li>• OSA</li><li>• Obesity hypoventilation syndrome</li><li>• Lymphedema</li><li>• Stress urinary incontinence</li><li>• GERD</li><li>• Prediabetes and metabolic syndrome</li><li>• MASLD</li><li>• Obesity glomerulopathy, CKD</li><li>• HFpEF</li><li>• ASCVD</li><li>• Thromboembolism</li><li>• Idiopathic intracranial hypertension</li><li>• Disability limiting activities of daily living</li></ul> | <b>Obesity-Related Diseases*</b> <ul style="list-style-type: none"><li>• T2D</li><li>• MASH</li><li>• HFrEF</li><li>• Atrial fibrillation</li><li>• Certain cancers</li><li>• Cholelithiasis, cholecystitis</li><li>• Asthma</li><li>• Depression, anxiety</li><li>• Internalized weight bias</li><li>• Stigmatization</li><li>• Disordered eating</li><li>• Cognitive decline, dementia</li><li>• Inflammatory skin diseases</li><li>• Intertrigo</li></ul> |
|                                                | *There can be overlap between complications and related diseases depending on the pathophysical role of obesity in individual patients. See Box A for definitions.                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

**Fig. 2.** Examples of ORCD that may be detected in the clinical evaluation of ABCD. Note that ABCD stages 2 and 3 in the AACE obesity algorithm do not differentiate between obesity complications and related diseases since both can be ameliorated by weight-loss therapy. ABCD = adiposity-based chronic disease; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; GERD = gastroesophageal reflux disease; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; MASH = metabolic dysfunction-associated steatohepatitis; MASLD = metabolic dysfunction-associated steatotic liver disease; OA = osteoarthritis; ORCD = obesity-related complications and diseases; OSA = obstructive sleep apnea; T2D = type 2 diabetes.



## Intake Evaluation of Individuals with ABCD

### Medical and Weight History

- life trajectory of weight
- previous efforts for weight loss

### Physical Exam

- include BMI
- waist
- waist-to-height ratio

### Social History\*

- preferences for diet
- physical activity
- social determinants of health
- smoking

### Laboratory

#### Obesity-Specific

- A1C
- fasting glucose
- lipid panel
- creatinine/eGFR
- ALT/AST/platelets for FIB-4

#### General Health if Needed

- CBC
- electrolytes/CMP
- urine analysis
- ECG

### Family History\*

#### Review of Systems\*

- shortness of breath
- orthopnea
- dyspnea on exertion
- chest pain
- palpitations
- syncope
- trouble sleeping
- polyuria
- bleeding history
- joint pain
- stress incontinence
- abdominal pain
- heartburn
- limitations in mobility and daily activities
- fatigue
- depression and stress
- anxiety
- internalized weight bias
- stigmatization

\*Can be obtained by questionnaire

### Directed Follow-Up

#### Testing Only If Indicated based on Intake Evaluation

- 2-hour OGTT
- ApoB
- CXR
- echocardiography
- ambulatory BP
- liver elastography
- liver biopsy
- polysomnography
- psychological evaluation
- TSH
- cortisol
- genetic testing (see text)
- sociology referral
- nutrition referral

**Fig. 3.** Intake evaluation of individuals with ABCD. A1C = hemoglobin A1C; ABCD = adiposity-based chronic disease; ALT = alanine transaminase; ApoB = apolipoprotein B; AST = aspartate aminotransferase; BMI = body mass index; BP = blood pressure; CBC = complete blood cell count; CMP = comprehensive metabolic panel; CXR = chest radiography; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; FIB-4 = fibrosis 4; OGTT = oral glucose tolerance test; TSH = thyroid-stimulating hormone.

should be considered in establishing their treatment goals, weight-reduction targets, and selection of lifestyle intervention, obesity medications, and/or bariatric surgery. The goals of therapy for each person with ABCD are to achieve reduction, stabilization, and maintenance of weight loss while preventing, mitigating, and treating ORCD and emphasizing overall health outcomes and quality of life.

To support the development of individualized care plans, it is important to assess:

1. History of early childhood obesity (onset before the age of 5 years) and/or early hyperphagia because this should prompt genetic testing with potential counseling for specific monogenic or syndromic etiologies of obesity<sup>71,72</sup>
2. Secondary etiologies or iatrogenic contributors such as weight-gain promoting medications, endocrinopathies, disability/immobility, and other medical conditions
3. Use of weight-promoting medications used to treat comorbidities and complications to the extent possible (eg, insulin, sulfonylureas, certain antipsychotics and antidepressants, corticosteroids)<sup>73</sup>
4. The impact of internalized weight bias and stigmatization on quality of life and the extent to which this could compromise a person's engagement in their therapeutic plan<sup>24,26</sup>
5. The presence of psychological disorders, such as depression, anxiety, and disordered eating, which may require intervention
6. Social determinants of health, health literacy, and access to health care and resources
7. A person's reasons for seeking care, treatment goals, and individual and cultural preferences for diet and physical activity


### Long-Term Follow-Up

People with ABCD have a lifelong disease and require long-term follow-up. The maintenance of weight loss is critical for sustaining health benefits. This is difficult over the long term because of the pathophysiology of metabolic adaptation with central and peripheral mechanisms driving weight regain, which is predictably associated with exacerbation or recurrence of ORCD. Individual weight maintenance plans must be personalized to address the environmental, behavioral, and physiological mechanisms through continued monitoring, lifestyle support, medical therapy, and follow-up to mitigate adverse health consequences. Modifications in lifestyle interventions and adjustments in obesity medications may be warranted, and this includes patients who have had bariatric surgery who often experience weight regain over time. The therapeutic approach to early weight loss may be different than that used to maintain weight loss over an extended period. Different or lower doses of obesity medications that are well-tolerated, accessible, and safe, particularly with respect to muscle and bone loss, may be advantageous. Further research and medication development is needed to inform optimal strategies for long-term effective and safe therapy.

### Individualization of Weight-Loss Targets

Algorithm 6 shows the range of therapeutic weight-reduction goals generally needed to achieve desired clinical health outcomes in complication-centric care. The weight-reduction target is based on the degree of weight loss that predictably ameliorates ORCD

RESPONSE TO THERAPY AND WEIGHT-LOSS TARGETS FOR PEOPLE WITH ABCD



Abbreviations: **ABCD**, adiposity-based chronic disease; **BMI**, body mass index; **CVD**, cardiovascular disease; **GERD**, gastroesophageal reflux disease; **HLD**, hyperlipidemia; **HTN**, hypertension; **MASH**, metabolic dysfunction-associated steatohepatitis; **MASLD**, metabolic dysfunction-associated steatotic liver disease; **OA**, osteoarthritis; **ORCD**, obesity-related complications and diseases; **OSA**, obstructive sleep apnea; **PCOS**, polycystic ovary syndrome; **T2D**, type 2 diabetes

Algorithm Figure 6 - Response to Therapy and Weight-Loss Targets

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



Algorithm 6. Response to therapy and weight-loss targets for people with adiposity-based chronic disease.

present in individual patients that are remediable in response to weight loss. As shown in Algorithm 6 and Table 2, treatment of different ORCD requires different degrees of weight loss. Percent weight reduction serves as a “biomarker” that can be targeted to assure sufficient weight loss required for predictable improvements in various ORCD as monitored by clinical findings, laboratory data (eg, blood pressure [BP], A1C, lipids, functional measures, etc.), and symptomatology reported by a patient.<sup>27</sup> Weight reduction and response to therapy are assessed both anthropometrically and clinically to inform the next steps in therapy. A person’s health guides the shared clinical decision-making discussion, including intensification or de-escalation of therapeutic interventions. The task force proposes categories of weight reduction correlating with clinical benefits as the following: (1)  $\leq 5\%$  indicates an incomplete response, because this is often insufficient to treat complications; (2)  $> 5\%$  to  $< 15\%$  indicates a good response, which may or may not be optimal for certain complications; and (3)  $\geq 15\%$  indicates an excellent response, because this is sufficient to treat or prevent a broad array of ORCD. Importantly, however, for any given intervention, the individual clinical response regarding improvements in obesity complications and the degree of weight loss are variable.<sup>139</sup> The goal is always to achieve sufficient weight loss needed for clinical improvement in each person.<sup>27,140</sup>

The early response to obesity medications should be assessed after about 3 months on the treatment dose. If the treatment has not resulted in at least a 5% weight reduction, longer-term efficacy will likely be insufficient, and this calls for a change in therapeutic approach whether this involves an intensification of lifestyle therapy, a different obesity medication, or a combination of obesity medications.<sup>141–146</sup> People who achieve weight reduction of  $\geq 5\%$  should continue with the current treatment. With ongoing follow-up, the need to intensify therapy may become evident if targets for improvement in ORCD are not being achieved.<sup>144–146</sup> The intensity of therapy both at initiation of treatment and with ongoing follow-up should correspond with the severity or stage of ABCD (Algorithm 6). Patients who experience a weight reduction of  $\geq 15\%$  (the level produced on average by second-generation obesity medications) will have achieved a response to therapy that predictably prevents or improves a broad array of ORCD<sup>25,27</sup> (Table 2 and Algorithm 6). When choosing an obesity medication that will achieve an individualized weight-reduction target, the relative efficacy for weight loss should be considered. This is made problematic by the lack of head-to-head comparison studies. However, in phase III trials, the average weight loss with first-generation medications approved for chronic therapy on or before 2014 is  $< 10\%$ , including orlistat, naltrexone/bupropion, liraglutide, and phentermine/topiramate. Of these medications, phentermine/topiramate appears

**Table 2**

Weight-Loss Targets Associated With Clinical Benefits for Different Adiposity-Based Chronic Disease Complications

| Obesity Complication or Related Disease     | Percent Weight Reduction Resulting in Clinically Meaningful Benefit              | Percent Weight Reduction Resulting in Additional Benefit                       |
|---------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| T2D prevention <sup>74-80</sup>             | 7%-10% (may vary if medication has glycemic benefits independent of weight loss) | >10% (may vary if medication has glycemic benefits independent of weight loss) |
| T2D remission <sup>81-85</sup>              | 10%                                                                              | >10%                                                                           |
| Improved hyperglycemia <sup>86-92</sup>     | 5%-15%                                                                           | >15%                                                                           |
| Hypertension <sup>86,93,94</sup>            | 5%-15%                                                                           | >15%                                                                           |
| Dyslipidemia <sup>86,95,96</sup>            | 5%-15%                                                                           | >15%                                                                           |
| Hepatic steatosis <sup>5,66-69,97-100</sup> | 5%-10%                                                                           | >10%                                                                           |
| MASH <sup>66,101-105</sup>                  | ≥10% (may vary if medication has benefits independent of weight loss)            | ≥15% (may vary if medication has benefits independent of weight loss)          |
| OSA <sup>106-109</sup>                      | 7%-10%                                                                           | >10%                                                                           |
| OA <sup>5</sup>                             | 5%-10%                                                                           | >10%                                                                           |
| Stress incontinence <sup>110-113</sup>      | 5%-10%                                                                           | >10%                                                                           |
| GERD <sup>114-116</sup>                     | 5%-10%                                                                           | >10%                                                                           |
| PCOS <sup>117-122</sup>                     | 5%-15%                                                                           | >15%                                                                           |
| Cancer prevention <sup>123-127</sup>        | Requires additional research                                                     |                                                                                |
| ASCVD and MACE <sup>88,128-138</sup>        | 10% (may vary if medication has benefits independent of weight loss)             | >10% (may vary if medication has benefits independent of weight loss)          |

Abbreviations: ASCVD = atherosclerotic cardiovascular disease; GERD = gastroesophageal reflux disease; MACE = major adverse cardiovascular events; MASH = metabolic dysfunction-associated steatohepatitis; OA = osteoarthritis; OSA = obstructive sleep apnea; PCOS = polycystic ovary syndrome; T2D = type 2 diabetes.

to be the most effective with average weight loss approaching 10%. Second-generation medications such as semaglutide and tirzepatide achieve on average of ≥15% weight loss in phase III trials. Setmelanotide produces this degree of weight loss in individuals with certain forms of monogenic obesity. In addition, evidence can now support hierarchies of preferred medications for complication-centric care based on the presence of specific ORCD, as discussed in [Algorithm 8](#). Maintaining weight reduction is crucial for preserving the health benefits of weight loss. Worsening ORCD accompany weight regain. De-escalation of specific therapies for ORCD (eg, medications for T2D, HTN, and hyperlipidemia) may begin after a modest reduction of initial weight and, thus, an individual's response must be monitored closely and medications adjusted as needed.<sup>81,147-149</sup>

### Metabolic and Bariatric Surgeries

Metabolic and bariatric surgeries, such as surgical sleeve gastrectomy, Roux-en-Y gastric bypass, and one anastomosis gastric bypass have been well established as highly efficacious treatment modalities for reducing weight and achieving clinical benefits for individuals with ABCD, especially those with BMI ≥40.0 kg/m<sup>2</sup> class 3 obesity or class 2 obesity with ORCD. Currently, the foremost procedures are surgical sleeve gastrectomy and Roux-en-Y gastric bypass (around 90% of operations globally), with each having well-studied mid- and long-term safety data in addition to efficacy outcomes.<sup>150</sup> Other operations performed include biliopancreatic diversion with duodenal switch, one anastomosis gastric bypass, and adjustable gastric banding, though the sub-optimal long-term efficacy of adjustable gastric banding has significantly diminished its use. Several bariatric procedures are now usually performed via minimally invasive surgical approaches (laparoscopic or robotic-assisted). Other endoscopic therapies that are short term, such as intragastric balloons, can be less efficacious and lacking in evidence for long-term benefits at the present time. Nevertheless, endoscopic devices may be considered and could represent effective adjunctive therapy in combination with obesity medications.

A BMI of ≥40.0 kg/m<sup>2</sup>, and a BMI of ≥35.0 kg/m<sup>2</sup> with ORCD, have long been the proposed thresholds for surgical indications. In 2016, 45 international professional societies issued a joint statement that metabolic surgery should be considered for people with

T2D and a BMI of 30.0 kg/m<sup>2</sup> to 34.9 kg/m<sup>2</sup> if hyperglycemia is inadequately controlled despite optimal treatment with either oral or injectable medications.<sup>151</sup> The American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders now recommend bariatric surgery as a treatment option for adults with BMI ≥35.0 kg/m<sup>2</sup>, regardless of the presence, absence, or severity of obesity-related conditions and also for adults with BMI of 30.0 kg/m<sup>2</sup> to 34.9 kg/m<sup>2</sup> who have severe cardiometabolic disease, such as T2D, and CVD.<sup>152,153</sup> These highly effective interventions should be combined with nutrition, physical activity, and behavioral therapy with the potential use of obesity medications before or after surgery if needed. A multidisciplinary team approach to perioperative and long-term care is mandatory for optimal clinical outcomes.<sup>154</sup> For further details beyond the scope of this consensus algorithm, see the 2020 Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures cosponsored by AACE, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists.<sup>155</sup>

In addition to obesity medications and surgical procedures, lifestyle interventions are essential to optimize health outcomes for people with ABCD. [Algorithm 7](#) shows nonpharmacologic interventions involving nutrition, physical activity, and sleep, while reducing stress and implementing individualized behavioral therapy.

### Nutrition

Nutrition and energy intake are critical components in the regulation of energy balance affecting the degree of adiposity. Exclusively focusing on “calories in, calories out” undermines the complexity of obesity pathophysiology and potentiates stigmatization. While weight reduction requires a change in energy balance to use stores greater than those replaced by dietary intake,<sup>156,157</sup> a healthy intake of macro- and micronutrients remains important and can help retain muscle and bone mass and promote health.

Nutritional interventions should focus on the quality and nutrient density of food consumed, while minimizing ultra-processed and energy-dense food intake, within the context of psychosocial cultural norms and preferences. Nutritional


interventions must create an energy deficit for weight reduction but can be challenging to sustain long-term in the absence of medical or surgical therapies. Despite efforts at adherence to dietary prescriptions, many people experience weight regain because of maladaptive responses after weight loss that are integral to the pathophysiology of obesity. Achieving an energy deficit for weight loss can be accomplished through a variety of evidence-based dietary strategies that need not be mutually exclusive and can be combined or modified in a personalized manner for individuals. Dietary patterns should be optimized to achieve health benefits beyond weight reduction and should reflect individual preferences, cultural context, health goals, and access to food. Special attention to diet quality should be given to those experiencing pronounced weight loss (ie, taking second-generation obesity medications) to ensure adequate intake of macro- and micronutrients (eg, protein, fiber, iron, calcium).

### Dietary Interventions

Individuals should receive counseling and support to create personalized nutrition plans in the context of autonomy accommodating dietary personal and cultural preferences while aligning with weight and health goals.<sup>74,158-164</sup> Numerous meal plans with variable macronutrient composition can be used in a

reduced-calorie format to safely promote weight reduction and health improvement. When lifestyle interventions are used as the single therapeutic modality, guidelines conventionally recommend caloric deficit plans of 500 to 750 kilocalories daily or estimated intakes of 1200 to 1500 kilocalories daily for women and men, respectively,<sup>5,165-167</sup> calculated based on the participants' baseline energy expenditure assessed at the time of randomization in trials (ie, using the National Institutes of Health calculator available at <https://www.niddk.nih.gov/bwp/>).<sup>168-174</sup> When considering a broad range of meal plans (Mediterranean, Dietary Approaches to Stop Hypertension, complex carbohydrate, low-carbohydrate, plant-based, paleo, etc.), there is no macronutrient composition known to be superior to others; rather, the most effective dietary intervention depends upon an individual's ability to adhere to it over the long term.<sup>175</sup> That said, safety data beyond 2 to 3 years are unavailable for many of these meal plans and longer-term cardiovascular (CV) risk reduction has been demonstrated only for the Mediterranean diet.<sup>176-179</sup> Meal replacement plans and timing of eating or fasting also may be implemented in combination with any other personalized dietary interventions.<sup>5,81,164,180-186</sup>

During the dose-escalation phase of obesity medications and the hypocaloric period of active weight loss, it is important to ensure adequate nutrition as well as dietary practices to minimize adverse events. With the powerful anorexigenic effects of second-



Abbreviation: **ABCD**, adiposity-based chronic disease


**Algorithm Figure 7 - Behavioral/Lifestyle Therapy**

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit [doi.org/10.1016/j.leprac.2025.07.017](https://doi.org/10.1016/j.leprac.2025.07.017) to request copyright permission.

**Algorithm 7.** Behavioral/lifestyle therapy for people with obesity/adiposity-based chronic disease.



## HIERARCHIES OF PREFERRED MEDICATIONS FOR COMPLICATION-CENTRIC CARE OF PEOPLE WITH ABCD



Abbreviations: **ABCD**, adiposity-based chronic disease; **HFpEF**, heart failure with preserved ejection fraction; **MACE**, major adverse cardiac events; **MASH**, metabolic dysfunction-associated steatohepatitis; **T2D**, type 2 diabetes

Algorithm Figure 8 - Preferred Medications Hierarchies

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



**Algorithm 8.** Hierarchies of preferred medications for complication-centric care of people with adiposity-based chronic disease.

generation obesity medications, the emphasis shifts from promoting reduced caloric intake to assuring nutritive diet quality. Several key guiding points: (1) optimize and prioritize nutrient-dense carbohydrates such as vegetables, beans/pulses, and fruits; (2) prioritize lean protein; (3) consider multivitamin supplementation to include iron and calcium; and (4) flexible use of meal replacements. For mitigating gastrointestinal side effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and other obesity medications, patients can be counseled to: (1) eat slowly to mitigate side effects of medications; (2) eat more frequently but consume smaller portions; (3) lower intake of fatty foods or foods that may exacerbate side effects; (4) track foods that may exacerbate gastrointestinal side effects; and (5) maintain adequate hydration.<sup>187</sup>

Dietary protein is the critical macronutrient to prioritize during weight reduction to potentially mitigate muscle loss.<sup>188–196</sup> High protein consumption was previously hypothesized to accelerate CKD; however, protein restriction (<0.8 g/kg) has not been shown to slow renal decline.<sup>197–199</sup> Recent guidance suggests maintaining a protein intake of  $\geq 1.2$  grams of protein per kilogram of body mass per day for most and  $\geq 0.8$  grams of protein per kilogram of body mass per day for those with diabetes mellitus and CKD not treated with dialysis.<sup>199,200</sup> Higher protein intakes ( $\geq 2.3$  g/kg/day) may be

needed to maximize the retention of lean body mass while prioritizing resistance training during hypocaloric periods.<sup>195,201,202</sup> Very high protein intake (>2 g/kg/day for prolonged periods) may not have adverse health effects, but the tolerable upper limit is thought to be  $\sim 3.5$  grams per kilogram of body mass per day.<sup>203</sup>

### Physical Activity

Physical activity, which includes aerobic activity, resistance/strength training, reduced sedentary time, and an increase in non-exercise activity thermogenesis, serves an important therapeutic role for people with obesity to improve overall health. Multiple guidelines for obesity and its complications, such as T2D, support physical activity prescription as an important part of therapy.<sup>165,180,128,204–207</sup> In particular, AACE suggests an individualized activity prescription in line with each individual's preferences and limitations (see Box B).<sup>5</sup> An eventual target of 150 minutes per week of moderate-intensity aerobic activity, divided into 3 or more days per week, is a general goal. Whole-body resistance training sessions at least 2 to 3 days per week are recommended and need to be prioritized, especially alongside intensive medical or surgical weight reduction, with the goal to maintain or improve lean muscle mass. Particular emphasis on



higher-volume physical activity is needed for an individual to maintain weight after behavioral, medical, and/or surgical weight reduction; in general, this should involve 200 to 300 minutes weekly of moderate-intensity aerobic exercise, again with a priority placed on resistance training for the preservation of lean muscle mass.<sup>208,209</sup> Retention of lean mass via resistance training during active weight reduction serves to preserve resting metabolic rate and overall energy expenditure.<sup>207,210–216</sup> Elderly individuals or those at risk of frailty (sarcopenic obesity) especially need to prioritize resistance training accompanied by adequate protein intake, because the loss of lean mass in these populations can be particularly harmful both metabolically and in terms of decreased function and risk of falls or fractures.<sup>213,217–219</sup>

Physical activity goals recommended in various guidelines can be difficult to achieve for people with obesity, especially when they first begin this physical activity. It is important to individualize the physical activity prescription based on the preferences and capabilities of each patient. Two adages apply: first, begin at a low intensity level and increase slowly as tolerated; second, any activity is better than none.<sup>1</sup> It can be a challenge for clinicians to assist a patient with limited exercise experience or with disabilities to safely begin an appropriate activity regimen. A practical first step may be to encourage simple and brief bouts of activity, such as a short walk during their lunch break or trying to stand more often throughout the day. Chair- or water-based exercises and consideration for physical therapy referral may benefit those with significant functional limitations to help find activities they can safely perform. When available, medical fitness programs, such as Exercise is Medicine, can be beneficial to safely introduce patients to resistance training and various exercises.<sup>220</sup>

## Box B

Physical Activity and Exercise Prescription for Obesity/Adiposity-Based Chronic Disease

- The exercise and physical activity prescription alone may result in modest (1% to 3%) weight reduction in some individuals or weight neutrality as individuals make up for expended calories with greater caloric ingestion. Nevertheless, exercise can have beneficial effects on insulin sensitivity, body composition, cardiometabolic risk factors, and sense of well-being, as well as help sustain weight loss in the weight-maintenance phase.
- Daily habits of "exercise" should be initiated at an individual's baseline ability and can include a variety of activities (eg, walking, swimming, biking, or other recreation).
- Frequency, intensity, and time duration should progress as a person is capable, which may include increasing speed, incline, and/or resistance. An eventual goal is  $\geq 150$  minutes per week of moderate-intensity physical activity, such as brisk walking, or  $\geq 75$  minutes per week of high-intensity physical activity, such as high-intensity interval training. Frequent and higher volumes of physical activity are required for maintenance of weight reduction.
- Strength/resistance training should be prioritized, especially in conjunction with highly effective obesity pharmacotherapy and/or surgery.

## Sleep

Suboptimal sleep duration ( $< 7$ –8 hours per night) and poor sleep quality can promote dysregulated energy intake, metabolic perturbations, and obesity.<sup>221–225</sup> Inadequate sleep and circadian disruption are associated with increased appetite, increased energy intake, decreased energy expenditure, and cardiometabolic disease risk.<sup>226</sup> For those with short sleep duration, individualized sleep hygiene counseling intended to extend sleep duration may reduce energy intake and increase weight reduction. OSA is a common obesity complication but remains underdiagnosed and often untreated.<sup>227</sup> The pathophysiological relationship between OSA and obesity is complex and multidirectional, and both are associated with insulin resistance and increased CV risks.<sup>64,228</sup> In the Sleep AHEAD (Action for Health in Diabetes) trial assessing a lifestyle intervention, weight reduction resulted in significant improvements in OSA and the apnea-hypopnea index among people with obesity and T2D.<sup>229</sup> Treating OSA with continuous positive airway pressure only, however, does not seem to improve weight reduction.<sup>230,231</sup> Sleep health is an important domain in the prevention and management of people with obesity and ORCD. People with obesity should be counseled about the importance of adequate sleep and circadian health. Screening for OSA is recommended in those with typical symptoms, high neck circumference ( $> 17$  inches in men and  $> 16$  inches in women), or high risk for OSA.<sup>232</sup>

## Bias, Stigma, Psychological Disorders, and Behavioral Therapy

Weight bias is defined as negative ideologies toward people living with obesity, and weight stigma denotes thoughts and acts of discrimination toward people living with obesity as a result of weight bias.<sup>26</sup> Verbal and nonverbal communication of stigma impact medical care and highlight systematic barriers to health care.<sup>233</sup>

Weight bias and stigmatization lead to internalized weight bias (IWB), when people apply negative weight stereotypes to themselves and engage in self-devaluation.<sup>24,26</sup> IWB negatively affects the physical and mental components of health-related quality of life and can compromise the ability to adhere to the therapeutic plan.<sup>234</sup> IWB is inversely related to motivation for healthy lifestyle behaviors and contributes to negative health outcomes.<sup>235</sup> For these reasons, AACE was the first to recommend taking IWB into account in the clinical evaluation and staging of people with obesity and in developing individualized treatment plans (Table 1).<sup>26</sup> The Weight Self-Stigma Questionnaire and the Weight Bias Internalization Scale are validated tools for assessing IWB in clinical settings.<sup>236,237</sup> IWB is the best predictor of stress, anxiety, depression, and body dissatisfaction.<sup>238</sup>

A person-centered approach to weight-based communication, using person-first language and conveying empathy when addressing health care concerns, is paramount.<sup>239</sup> Individuals should be presented with the full range of evidence-based medical and surgical treatment options in addition to lifestyle interventions.<sup>233</sup> Health care professionals should communicate the risks versus benefits of treating obesity by emphasizing benefits related to their health with messaging tailored to different degrees of health literacy.<sup>180</sup> Cognitive behavioral therapy can aid people with obesity in maintaining healthy lifestyle choices by fostering cognitive changes oriented toward supporting weight reduction while optimizing health.<sup>240</sup>

Health care professionals should consider the psychological overlay of overweight/obesity and possibility of psychological disorders in people with ABCD. Depression, anxiety, and binge-eating disorder are more prevalent among people with obesity

compared with the general population.<sup>241</sup> These issues can require immediate intervention in some patients to assure that the therapeutic plan can be effective. Consultation with trained professionals for psychological screening and cognitive behavioral therapy should be considered as part of long-term follow-up for people with IWB. Collaboration with a psychological specialist by referral or as a member of the multidisciplinary obesity care team is important for the provision of holistic care for people with ABCD.<sup>242</sup>

Algorithm 8 provides guidance to assist clinicians as they personalize therapy based on complication-centric care targeting specific ORCD. Hierarchies of preferred medications are recommended based on clinical trial data. These hierarchies are supported by phase III clinical trials that have addressed the ability of obesity medications to treat ORCD as primary or predesignated outcome measures. This does not negate the possibility that weight loss regardless of treatment modality may provide benefit as indicated in the algorithm.

## Cardiometabolic ORCD

### *Prediabetes Metabolic Syndrome and Diabetes Prevention*

Semaglutide<sup>243</sup> or tirzepatide<sup>244</sup> are preferred medications for preventing progression to overt diabetes because of substantial weight loss and direct glycemic effects as incretins in addition to other clinically significant cardiometabolic benefits pertaining to improvements in lipids, BP, and inflammation.<sup>5,28,81</sup> Liraglutide<sup>75</sup> and phentermine/topiramate<sup>59,76</sup> are second-tier medications but highly effective in this regard. Orlistat is a third-tier medication.<sup>245</sup>

### *T2D*

Tirzepatide<sup>246</sup> and semaglutide<sup>247</sup> are first-tier medications for treating people with T2D and obesity based on weight loss achieved, degree of lowering A1C to target, and low rates of hypoglycemia. Liraglutide<sup>248</sup> and phentermine/topiramate<sup>76</sup> are second-tier medications but effective in the treatment of these individuals. Orlistat<sup>249</sup> and naltrexone/bupropion<sup>250</sup> are considered third-tier medications.

### *Major Adverse Cardiovascular Event Prevention*

Semaglutide is the only obesity medication, thus far, that has been shown to reduce risks of major adverse cardiovascular events (MACE) in a cardiovascular outcome trial (CVOT) involving secondary prevention in people with obesity and not diabetes.<sup>129</sup> Tirzepatide may also be efficacious for cardioprotection based on post hoc analyses of the SURMOUNT 1 extension trial, which showed reduced hazard ratios for MACE.<sup>251</sup> Liraglutide 1.8 mg per day demonstrated cardioprotection in people with obesity and T2D in the LEADER CVOT.<sup>129,252</sup> A morbidity and mortality outcome trial is ongoing for tirzepatide. Definitive data for cardioprotection are lacking for orlistat, naltrexone/bupropion, and phentermine/topiramate.

### *Metabolic Dysfunction-Associated Steatohepatitis*

Semaglutide<sup>101,100</sup> and tirzepatide<sup>102</sup> are preferred medications for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) based on data showing improvements in hepatic histology and fibrosis.<sup>66</sup> Any weight-loss intervention that achieves 5% to 10% weight loss or more will predictably reduce hepatic steatosis.<sup>5</sup>

### *HTN/BP Lowering*

Tirzepatide and semaglutide, followed by phentermine/topiramate extended release (ER) are preferred medications for those with ABCD complicated by HTN based upon improvement of BP in clinical trials.<sup>93,253–259</sup> Liraglutide<sup>260</sup> and orlistat are considered second-tier medications.<sup>261,262</sup>

### *CKD*

Semaglutide is the preferred medication for treatment of CKD, based on clinical trial data in people with T2D showing that a dose of 1 mg per week will slow the rate of decline of estimated glomerular filtration rate and prevent renal outcomes.<sup>263</sup> Liraglutide in patients with T2D at a dose of 1.8 mg per day was also shown to be renal protective in a secondary analysis of the LEADER trial.<sup>264</sup> A clinical trial primarily assessing the impact of tirzepatide on renal function is ongoing, and a post hoc analysis of a previous trial in people with T2D supports the expectation that tirzepatide will show positive results.<sup>265</sup>

### *HFpEF*

Tirzepatide has been shown to improve symptoms, physical function, and heart failure outcomes (eg, the need for urgent care visits or hospitalization) in people with HFpEF, and semaglutide to improve symptoms and physical function in these individuals.<sup>266,267</sup>

## Biomechanical ORCD

### *OA*

Semaglutide is the preferred medication for individuals with obesity complicated by OA of the knee based on clinical trial data.<sup>268</sup> Weight loss of >5% can improve symptoms of OA.<sup>1</sup>

### *OSA*

Tirzepatide and phentermine/topiramate are preferred medications for the treatment of OSA in people with ABCD based on clinical trial data that showed improvements in symptoms and the apnea-hypopnea index during polysomnography.<sup>106,269–271</sup> Tirzepatide is now approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate and severe OSA in adults with obesity.<sup>272</sup>

### *Dual Benefits Regarding Comorbidities*

Clinicians should consider the dual benefits of obesity medications (eg, efficacy for weight loss and demonstrated ability to ameliorate specific complications or comorbidities unrelated to obesity), known adverse effects, and cost of available medications. When cost and coverage create barriers to access, consider off-label generic medications with evidence for therapeutic potential. In addition to ameliorating specific ORCD, topiramate, phentermine/topiramate, liraglutide, and semaglutide have shown benefits for binge-eating syndrome or food cravings, with likely beneficial, but mixed, results for naltrexone/bupropion.<sup>273,274</sup> Other indications to consider for specific medications include topiramate for migraines, naltrexone and GLP-1 RAs for alcohol use dependence, and bupropion for treatment of smoking cessation.<sup>275–277</sup> While pharmacotherapy to treat regain or achieve clinical goals after bariatric/metabolic surgery is not specifically addressed, it should be noted that obesity

medications may be an effective tool to support patients postsurgery.<sup>278,279</sup>

Second-generation obesity medications are highly expensive, particularly in the United States, and people often lack insurance coverage and access to these evidence-based therapies.<sup>280</sup> It is important to keep in mind that first-generation medications (eg, phentermine, orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide) can effectively be used for weight loss and treatment of ORCD in many people. These medications are less expensive and more accessible and can be considered in people with stage 1 or 2 ABCD, although second-generation medications should be used whenever possible in stage 3 disease if needed for sufficient weight loss to treat more serious complications. First-generation medications have been demonstrated in clinical trials to effectively ameliorate certain obesity complications and can be used to benefit BP and lipids, hepatic steatosis, diabetes prevention (liraglutide and phentermine/topiramate), treatment of OSA (phentermine/topiramate), treatment of T2D (all first-generation medications), and cardioprotection and renal protection in those with T2D (liraglutide).<sup>1</sup> If weight loss is insufficient to achieve clinical goals, an alternative first-generation medication, intensification of behavioral or lifestyle interventions, or switch to a second-generation medication should be considered (see [Algorithm 9](#)). The health of an individual through the achievement of clinical goals in complication-centric care is critical. Complications and related diseases can also be treated with specific therapies that are not related to weight loss. In addition, a trial of first-generation medication to maintain weight loss after initial treatment using a second-generation medication can also be considered an option with better cost and access for long-term maintenance.

[Algorithm 10](#) provides guidance to help individualize the choice of pharmacotherapy, taking into consideration ORCD, comorbidities, and potential adverse events, although the list of obesity-related conditions is not exhaustive. The table is color coded as follows: (1) blue: evidence of benefit; (2) gray: insufficient evidence, but obesity medication may still be considered; (3) yellow: caution or extra monitoring recommended; and (4) orange: known contraindications. Clinicians should refer to additional details in the FDA prescribing information.

[Algorithm 11](#) provides key information for prescribing obesity medications that are currently approved by the FDA for obesity (ie, “chronic weight management”), including considerations involving age, dose, titration, observed efficacy, cost, and cautions or contraindications. Additional salient details for each medication are provided below, focusing on outcomes in individuals with obesity. Clinicians are encouraged to read and review FDA labels (package inserts) for each obesity medication for more detailed information.

### Orlistat

Orlistat was approved by the FDA for chronic weight management (obesity treatment) in 1999. It results in weight reduction by inhibiting pancreatic and gastric lipases and reducing fat absorption by approximately 30%. In the XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study, the mean weight reduction after 4 years was significantly greater in the orlistat group than with placebo (5.8 vs 3.0 kg, respectively).<sup>245</sup> Treatment with orlistat also resulted in a significant reduction in the cumulative incidence of T2D after 4 years of treatment (9.0% with placebo vs 6.2% with orlistat), corresponding to a risk reduction of 37.3%.<sup>245</sup> Other benefits of orlistat include a reduction in low-density lipoprotein cholesterol independent of that expected from change in body weight. Two doses for orlistat are currently approved by the FDA for obesity, 120 mg orally 3 times a day before

meals (by prescription) and 60 mg orally 3 times a day before meals (over the counter).

Side effects of orlistat include steatorrhea, incontinence, oily spotting, frequent bowel movements, abdominal pain, flatulence with discharge, and fecal urgency, especially after high-fat dietary intake. Serum levels of fat-soluble vitamins (A, D, E, and K) have shown to be lower with orlistat than with placebo, so a fat-soluble vitamin supplement (including vitamins A, D, E, and K) is recommended at bedtime or  $\geq 2$  hours after orlistat dose.<sup>281,282</sup> Kidney and liver function should be monitored while taking orlistat. Serious but infrequent adverse events such as liver injury, cholelithiasis, nephrolithiasis, and kidney damage have been reported.<sup>283,284</sup> Orlistat is not recommended for patients with malabsorption disorders.<sup>285,286</sup>

### Phentermine and Other Norepinephrine-Releasing Agents

Phentermine is a central norepinephrine-releasing agent approved in 1959 for short-term weight loss (“a few weeks,” per the FDA label). As obesity is a chronic disease, phentermine is commonly prescribed off-label beyond 3 months and has been the most prescribed obesity medication in the United States.<sup>287–290</sup> Frequently raised concerns for long-term CV safety, with prospective CV safety data lacking, are now being addressed in the ongoing Long-term Effectiveness of the Anti-Obesity Medication Phentermine (LEAP) National Institutes of Health–funded trial (NCT05176626).<sup>291</sup> Studies of phentermine in adults have demonstrated only transient changes in BP, but retrospective data have demonstrated overall long-term safety and effectiveness.<sup>292–294</sup>


Phentermine is available as a tablet or capsule; the initial recommended dose is 8 mg or 15 mg with maximum dose of 37.5 mg taken once daily or 8 mg up to 3 times daily (24 mg total). Short-term studies ranging from 12 to 28 weeks have demonstrated average weight reduction of 5.45% to 7.7% with the use of phentermine.<sup>295,296</sup> Most longer-term data on the use of phentermine comes from trials using a combination of phentermine and topiramate, where medications were continued for up to 2 years.<sup>260,292</sup>

The most common side effects reported with phentermine include headaches, elevation of BP and heart rate, insomnia, dry mouth, constipation, and anxiety. Phentermine use is contraindicated in people with a history of CVD (coronary artery disease, uncontrolled HTN, arrhythmias, stroke, congestive heart failure), hyperthyroidism, glaucoma, and a history of drug use disorder, or those who are pregnant or breastfeeding.<sup>5,73</sup> Included in the class of norepinephrine-releasing agents approved for obesity is diethylpropion (or amfepramone), phendimetrazine, and benzphetamine.

### Phentermine and Topiramate ER

Phentermine and topiramate ER as a combination therapy was approved by the FDA for chronic weight management in 2012 and for adolescents  $\geq 12$  years of age in 2022 with its efficacy and safety studied in several randomized controlled trials.<sup>168,260,295,297</sup> The mechanism of action for weight reduction of topiramate is not well understood but is thought to be related to modulating gamma-aminobutyric acid release, blocking glutamate release.<sup>298</sup> Four different oral doses are available: the starting dose is 3.75/23 mg for 14 days followed by a maintenance dose of 7.5/46 mg daily, with 2 higher doses of 11/69 mg and 15/92 mg available if needed. Results from several clinical trials (EQUIP, CONQUER, and SEQUEL) demonstrated weight reduction in the treatment group (phentermine and topiramate ER), ranging from 7.8% to 10.7% compared with 1.2% to 2.2% in the placebo group on both completers and intent-to-treat groups.<sup>168,260,299</sup>

## LOWER-COST PHARMACOLOGIC STEP THERAPY FOR ABCD



<sup>a</sup> 1st-generation obesity medications: phentermine, phentermine/topiramate ER, naltrexone/bupropion ER, liraglutide

<sup>b</sup> 2nd-generation more effective obesity medications: semaglutide, tirzepatide

Abbreviations: ABCD, adiposity-based chronic disease; ER, extended release

Algorithm Figure 9 - Lower-Cost Pharmacologic Step Therapy

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.



Algorithm 9. Lower-cost pharmacologic step therapy for adiposity-based chronic disease.

The side-effect profile of phentermine and topiramate ER is similar to phentermine with the addition of side effects from topiramate. Some of topiramate's common side effects include dysgeusia, paresthesia, cognitive side effects such as drowsiness or word aphasia, and constipation. Topiramate can also cause hypokalemia, metabolic acidosis, and nephrolithiasis as a carbonic anhydrase inhibitor. The combination of phentermine and topiramate ER is contraindicated in pregnancy (known teratogenicity) and breastfeeding, glaucoma, and untreated hyperthyroidism. A risk evaluation and mitigation strategy is required by the FDA for phentermine/topiramate ER to inform certified pharmacies and patients of reproductive potential about the increased risk of embryo-fetal toxicity with major congenital malformations. Pregnancy prevention is mandatory. A negative pregnancy test is recommended before initiating monthly monitoring. If pregnancy occurs, phentermine/topiramate ER must be discontinued immediately. People who receive higher doses are prone to more side effects. While the CV safety of phentermine and topiramate ER is not established, data from the phase III trials do not raise signal of concern.<sup>300</sup> Small increases in heart rate are well balanced by decreases in BP such that the rate-pressure product is favorable. Phentermine and topiramate ER have been shown to effectively ameliorate OSA,<sup>106</sup> to prevent progression from metabolic

syndrome or prediabetes to T2D,<sup>59</sup> and in T2D to promote weight loss and lower A1C with less need for conventional diabetes medications.<sup>76</sup>

### Naltrexone/Bupropion ER

Naltrexone/bupropion ER is an ER combination of naltrexone, an opioid antagonist, and bupropion, a noradrenergic/dopaminergic reuptake inhibitor antidepressant, approved by the FDA in 2014 for chronic weight management in adults.<sup>301</sup> Although the exact mechanism of action is not fully understood, studies suggest that the combined action of naltrexone and bupropion leads to a synergistic effect in regulating food intake with effects on the hypothalamus (appetite regulatory centers) and on the mesolimbic dopamine circuit (reward system).<sup>302</sup>

Each tablet of naltrexone/bupropion ER contains 8 mg naltrexone and 90 mg bupropion. Dose escalation starts with 1 tablet once daily for the first 7 days, increased by 1 tablet weekly up to a final dose of 2 tablets twice daily (naltrexone 32 mg/bupropion ER 360 mg). Caution is advised for its use in patients >65 years of age as they may have increased sensitivity to naltrexone/bupropion's adverse effects on the central nervous system. There are no safety and efficacy data for patients <18 years



| MEDICATIONS FOR OBESITY: INDIVIDUALIZATION OF THERAPY <sup>a</sup>                                                                                                                    |                                 |                                     |                                                                    |                                     |                                                     |                                                     |                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------------|--------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| KEY: <span>Preferred (evidence of benefit)</span> <span>Insufficient evidence to prefer</span> <span>Monitoring indicated</span> <span>Contraindicated (evidence of risk/harm)</span> |                                 |                                     |                                                                    |                                     |                                                     |                                                     |                                                     |
| OBESITY-RELATED CONDITION                                                                                                                                                             | ORLISTAT                        | PHENTERMINE                         | PHENTERMINE/ TOPIRAMATE ER                                         | NALTREXONE ER/ BUPROPION ER         | LIRAGLUTIDE                                         | SEMAGLUTIDE                                         | TIRZEPATIDE                                         |
| DIABETES PREVENTION                                                                                                                                                                   | Benefit via weight reduction    |                                     | Benefit via weight reduction                                       |                                     | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    |
| TYPE 2 DIABETES                                                                                                                                                                       | Benefit via weight reduction    |                                     | Benefit via weight reduction                                       | Benefit via weight reduction        | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    |
| HYPERTENSION                                                                                                                                                                          | Benefit via weight reduction    | Monitor heart rate, BP              | Monitor heart rate, BP; BP benefit observed in trials <sup>b</sup> | Monitor heart rate, BP              | BP benefit observed in trials; Monitor heart rate   | BP benefit observed in trials; Monitor heart rate   | BP benefit observed in trials; Monitor heart rate   |
|                                                                                                                                                                                       |                                 | Contraindicated in uncontrolled HTN |                                                                    | Contraindicated in uncontrolled HTN |                                                     |                                                     |                                                     |
| ASCVD                                                                                                                                                                                 |                                 | Contraindicated                     | Use with caution; Monitor heart rate, BP                           | Monitor heart rate, BP              | Demonstrated prevention of ASCVD in T2D             | Demonstrated prevention of ASCVD                    | Evidence in T2D and obesity pending                 |
| MASLD                                                                                                                                                                                 |                                 |                                     |                                                                    |                                     | Benefit observed in trials                          | Benefit observed in trials                          | Benefit observed in trials                          |
| DEPRESSION                                                                                                                                                                            |                                 |                                     | Appropriate monitoring                                             | Appropriate monitoring              | Appropriate monitoring                              | Appropriate monitoring                              | Appropriate monitoring                              |
| ANXIETY                                                                                                                                                                               |                                 | Appropriate monitoring              | Appropriate monitoring                                             | Appropriate monitoring              |                                                     |                                                     |                                                     |
| CHRONIC KIDNEY DISEASE                                                                                                                                                                | Monitor for oxalate nephropathy |                                     | Do not exceed 7.5 mg/46 mg per day                                 | Do not exceed 8 mg/90mg twice a day | Benefit in T2D; Avoid vomiting and volume depletion | Benefit in T2D; Avoid vomiting and volume depletion | Benefit in T2D; Avoid vomiting and volume depletion |
| SEVERE KIDNEY IMPAIRMENT                                                                                                                                                              | Monitor for oxalate nephropathy | Urinary clearance of drug           | Urinary clearance of drug                                          | Urinary clearance of drug           | Avoid vomiting and volume depletion                 | Avoid vomiting and volume depletion                 | Avoid vomiting and volume depletion                 |
| NEPHROLITHIASIS                                                                                                                                                                       | Calcium oxalate stones          |                                     | Calcium phosphate stones                                           |                                     |                                                     |                                                     |                                                     |
| HEPATOBIILIARY IMPAIRMENT                                                                                                                                                             | Monitor for cholelithiasis      | Do not exceed 8 mg per day          | Do not exceed 7.5 mg/46 mg per day                                 | Do not exceed 8 mg/90 mg daily      | Monitor for cholelithiasis                          | Monitor for cholelithiasis                          | Monitor for cholelithiasis                          |
| SEVERE HEPATIC IMPAIRMENT                                                                                                                                                             | Not recommended                 |                                     |                                                                    |                                     |                                                     |                                                     |                                                     |

<sup>a</sup> All medications are contraindicated in pregnancy and breastfeeding. <sup>b</sup> Blood pressures are significantly decreased in clinical trials.

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; ER, extended release; HTN, hypertension; T2D, type 2 diabetes

Algorithm Figure 10 - Medications for Obesity: Individualization of Therapy

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.



Algorithm 10. Medications for obesity: individualization of therapy.

of age, and this medication is not recommended for individuals <18 years of age.

In 4 56-week phase III trials,<sup>169,250,303,304</sup> treatment with naltrexone/bupropion 32 mg/360 mg led to clinically significant weight reduction, ranging from 5.9% to 11.5% compared with placebo among completers. The initial 3 trials focused on those with obesity alone or with obesity and controlled HTN and/or dyslipidemia. Participants of these trials lost nearly 12% on average if achieving 5% weight reduction in the first 3 months of full dosing.<sup>305</sup>

Naltrexone/bupropion ER should be avoided with fatty meals, as this can result in a significant increase in both drug levels systemically. There is a recommended dose adjustment for those with renal and hepatic impairment. The maximum dose of naltrexone/bupropion ER is 1 tablet twice daily for those with moderate to severe renal impairment/or moderate hepatic impairment. Naltrexone/bupropion ER is not recommended with end-stage renal disease or with severe hepatic impairment.

Common side effects include nausea, headache, constipation, dizziness, vomiting, and dry mouth, with occurrences ranging from approximately 4% to 32%.<sup>301</sup> A slight elevation in BP and heart rate have been observed, so it is important to monitor BP and heart rate at the start of therapy and at regular intervals. A CVOT was

initiated for naltrexone/bupropion ER, but the trial was terminated because of public compromise of the data; thus, CV safety has not been determined.<sup>306</sup> Use caution with patients taking beta blockers, as naltrexone/bupropion ER may increase levels of beta blockers; consider starting the medication at a lower dose while closely monitoring heart rate. Contraindications include uncontrolled HTN; seizure disorders (can lower seizure threshold); anorexia nervosa or bulimia; abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs; use of other bupropion-containing products; chronic opioid use; during or within 14 days of taking monoamine oxidase inhibitors; known allergies to any of the drug's ingredients; and pregnancy.

Liraglutide

Liraglutide is a daily injectable GLP-1 RA. Originally approved by the FDA for T2D in 2010 at a dose of 1.8 mg per day, liraglutide was the first GLP-1 RA approved by the FDA for chronic weight management (obesity) treatment (2014) in adults and in adolescents (2020) at a dose of 3.0 mg per day. In addition to its well characterized incretin effect, endogenous GLP-1 impacts weight homeostasis by acting centrally in various regions of the brain, including in the hypothalamus, directly activating proopiomelanocortin



| MEDICATIONS FOR OBESITY APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION <sup>a,b</sup> |                                                                                                                                                |                                                                                                                                                 |                                                                                                                                                                                                         |                                                                                                                                                                                                                                          |                                                                                                                                                                                         |                                                                                                                                                                                                |                                                                                                                                                                                                                   |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                          | ORLISTAT                                                                                                                                       | PHENTERMINE <sup>c</sup>                                                                                                                        | PHENTERMINE/<br>TOPIRAMATE ER                                                                                                                                                                           | NALTREXONE ER/<br>BUPROPION ER                                                                                                                                                                                                           | LIRAGLUTIDE                                                                                                                                                                             | SEMAGLUTIDE                                                                                                                                                                                    | TIRZEPATIDE                                                                                                                                                                                                       |
| CLASS/MECHANISM OF ACTION                                                                | Lipase Inhibitor                                                                                                                               | NE-Releasing Agent                                                                                                                              | NE-Releasing Agent<br>GABA Receptor Modulation                                                                                                                                                          | Opioid-Receptor Antagonist<br>DA-NE Reuptake Inhibitor                                                                                                                                                                                   | GLP-1 RA                                                                                                                                                                                | GLP-1 RA                                                                                                                                                                                       | GIP/GLP-1 RA                                                                                                                                                                                                      |
| AGE                                                                                      | ≥12 years <sup>d</sup>                                                                                                                         | >16 years                                                                                                                                       | ≥12 years                                                                                                                                                                                               | ≥18 years <sup>d</sup>                                                                                                                                                                                                                   | ≥12 years <sup>e</sup>                                                                                                                                                                  | ≥12 years <sup>e</sup>                                                                                                                                                                         | ≥18 years <sup>d</sup>                                                                                                                                                                                            |
| DELIVERY                                                                                 | Oral                                                                                                                                           | Oral                                                                                                                                            | Oral                                                                                                                                                                                                    | Oral                                                                                                                                                                                                                                     | Subcutaneous Injection                                                                                                                                                                  | Subcutaneous Injection                                                                                                                                                                         | Subcutaneous Injection                                                                                                                                                                                            |
| STARTING DOSE                                                                            | 60 mg 3 times/day AC                                                                                                                           | 8 mg or 15 mg QAM                                                                                                                               | 3.75 mg/23 mg QAM                                                                                                                                                                                       | 8 mg/90 mg QAM                                                                                                                                                                                                                           | 0.6 mg QD                                                                                                                                                                               | 0.25 mg QWK                                                                                                                                                                                    | 2.5 mg QWK                                                                                                                                                                                                        |
| DOSE ESCALATION                                                                          | Titrate up to needed dose<br><br>Slow dose titration if side effects occur<br><br>Formulations:<br>60 mg cap<br>120 mg cap                     | Titrate up to needed dose<br><br>Slow down dose titration if side effects occur<br><br>Formulations:<br>8 mg tab<br>15 mg cap<br>37.5 mg tab    | Titrate up bi-weekly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>3.75 mg/23 mg QAM x 2 wk<br>7.5 mg/46 mg QAM x 12 wk<br>11.25 mg/69 mg QAM x 2 wk<br>15 mg/92 mg QAM   | Titrate up weekly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>8 mg/90 mg QAM x 1 wk<br>8 mg/90 mg twice daily x 1 wk<br>16 mg/90 mg QAM and 8 mg/90 mg QPM x 1 wk<br>16 mg/90 mg twice daily             | Titrate up weekly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>0.6 mg QD x 1 wk<br>1.2 mg QD x 1 wk<br>1.8 mg QD x 1 wk<br>2.4 mg QD x 1 wk<br>3.0 mg QD | Titrate up monthly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>0.25 mg QWK x 4 wk<br>0.5 mg QWK x 4 wk<br>1.0 mg QWK x 4 wk<br>1.7 mg QWK x 4 wk<br>2.4 mg QWK | Titrate up monthly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>2.5 mg QWK x 4 wk<br>5.0 mg QWK x 4 wk<br>7.5 mg QWK x 4 wk<br>10 mg QWK x 4 wk<br>12.5 mg QWK x 4 wk<br>15 mg QWK |
| MAXIMUM DOSE                                                                             | 120 mg 3 times/day AC                                                                                                                          | 37.5 mg QAM <sup>f</sup>                                                                                                                        | 15 mg/92 mg QD                                                                                                                                                                                          | 16 mg/180 mg twice daily                                                                                                                                                                                                                 | 3.0 mg QD                                                                                                                                                                               | 2.4 mg QWK                                                                                                                                                                                     | 15 mg QWK                                                                                                                                                                                                         |
| WEIGHT REDUCTION <sup>g</sup>                                                            | 4%<br>(52 weeks)                                                                                                                               | 5%–8%<br>(28 weeks)                                                                                                                             | 9.6%–9.9%<br>(52 weeks) dose dependent                                                                                                                                                                  | 4.2%–5.2%<br>(52 weeks)                                                                                                                                                                                                                  | 9.2%<br>(56 weeks)                                                                                                                                                                      | 16.9%<br>(68 weeks)                                                                                                                                                                            | 22.5%<br>(72 weeks)                                                                                                                                                                                               |
| POTENTIAL SIDE EFFECTS <sup>h</sup>                                                      | Flatulence<br>Fecal Urgency<br>Oily Stools<br>Fat-Soluble Vitamin and Drug Malabsorption<br>Potential Drug-Drug Interactions                   | Restlessness<br>Insomnia<br>Headache<br>Dry Mouth<br>Tachycardia<br>BP Elevation                                                                | Paresthesia, Dizziness<br>Dysgeusia, Insomnia<br>Constipation, Dry Mouth<br>Fatigue<br>Blurred Vision<br>Mental Clouding<br>Mood Changes                                                                | Nausea, Constipation<br>Headache<br>Vomiting<br>Dizziness<br>Insomnia<br>Dry Mouth, Diarrhea Anxiety                                                                                                                                     | Nausea<br>Diarrhea<br>Constipation<br>Dyspepsia<br>Vomiting<br>Abdominal Pain<br>GERD                                                                                                   | Nausea, Diarrhea<br>Constipation<br>Dyspepsia<br>Vomiting<br>Abdominal Pain<br>Headache<br>Fatigue                                                                                             | Nausea, Diarrhea<br>Constipation<br>Dyspepsia<br>Vomiting<br>Abdominal Pain<br>Headache<br>Fatigue                                                                                                                |
| CAUTIONS, RELATIVE AND ABSOLUTE CONTRAINDICATIONS <sup>i</sup>                           | Cholestasis<br>Chronic Malabsorption Syndrome<br>Nephrolithiasis<br>Vitamin Malabsorption<br>Encourage Supplementation<br>Potential for Misuse | CAD, CVA, Arrhythmias, CHF, Uncontrolled HTN, Hyperthyroidism<br>Agitated States<br>History of Drug Abuse<br>MAOI Use<br>Angle-Closure Glaucoma | MAOI<br>Hyperthyroidism<br>Angle-Closure Glaucoma<br>Monitor for Increased Heart Rate<br>Nephrolithiasis<br>Metabolic Acidosis <sup>c</sup><br>Monitor for Worsening Anxiety or Depression <sup>c</sup> | Seizure Disorder<br>Uncontrolled HTN<br>Chronic Opioid Use<br>Anorexia Nervosa<br>Bulimia Nervosa<br>MAOI Use<br>Abrupt Drug or Alcohol Withdrawal<br>Angle-Closure Glaucoma<br>Monitor for Worsening Anxiety or Depression <sup>c</sup> | History or Family History<br>MTC/MEN2<br>Gallbladder Disease<br>Pancreatitis<br>Increased Heart Rate                                                                                    | History or Family History<br>MTC/MEN2<br>Gallbladder Disease<br>Pancreatitis<br>Diabetic Retinopathy <sup>j</sup>                                                                              | History or Family History<br>MTC/MEN2<br>Gallbladder Disease<br>Pancreatitis<br>Diabetic Retinopathy <sup>j</sup>                                                                                                 |
| ACCESS/COST                                                                              | \$\$                                                                                                                                           | \$                                                                                                                                              | \$\$                                                                                                                                                                                                    | \$\$                                                                                                                                                                                                                                     | \$\$\$                                                                                                                                                                                  | \$\$\$\$                                                                                                                                                                                       | \$\$\$\$                                                                                                                                                                                                          |

<sup>a</sup>Monogenic obesity treatment, devices for weight reduction, and setmelanotide can be found in narrative. <sup>b</sup>FDA-approved for CWM. <sup>c</sup>This class of medications includes diethylpropion (or amfepramone), phendimetrazine, and benzphetamine. <sup>d</sup>EMA approved for age 16 years and above for CWM. <sup>e</sup>EMA approved for age 12 years and above for CWM. <sup>f</sup>Maximum dose allowed for phentermine; however, many patients will see results on 8 mg 3 times a day which is also considered a maintenance dose in patients with diabetes and obesity. <sup>g</sup>Percent body weight reduction in treatment in phase III trial. <sup>h</sup>Complications requiring caution or monitoring in order of observed frequency. <sup>i</sup>All FDA-approved medications for obesity are contraindicated in individuals who are pregnant or breastfeeding; effective birth control should be recommended/prescribed. A negative pregnancy test is recommended before initiating, with monthly monitoring. <sup>j</sup>In patients with T2D and obesity. <sup>k</sup>Blood pressures are significantly decreased in clinical trials for phentermine/topiramate ER.

Abbreviations: AC, before meals; BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebrovascular accident; CWM, chronic weight management; DA, dopamine; EMA, European Medicines Agency; ER, extended release; FDA, U.S. Food and Drug Administration; GERD, gastroesophageal reflux disease; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HTN, hypertension; MAOI, monoamine oxidase inhibitors; MEN2, multiple endocrine neoplasia, type 2; MTC, medullary thyroid cancer; NE, norepinephrine; QAM, every morning; QD, every day; QPM, every afternoon or evening; QWK, every week; wk, week(s).

Algorithm Figure 11 - FDA-Approved Medications for Obesity: Prescribing Information

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.



Algorithm 11. Medications for obesity approved by the U.S. Food and Drug Administration.

(POMC)/cocaine- and amphetamine-regulated transcript neurons and indirectly inhibiting the neuropeptide Y/agouti-related peptide neurons,<sup>307–309</sup> as well as having action in the brain stem.

Liraglutide has a half-life of 13 hours, allowing it to be given once daily. It is titrated up weekly as tolerated by the patient from a starting dose of 0.6 mg. Liraglutide is approved by the FDA for obesity (chronic weight management) for patients ≥12 years of age at a dose of 3.0 mg daily.<sup>310</sup> Efficacy and safety in adults were examined in the SCALE Obesity and Prediabetes trial, in which liraglutide 3 mg daily resulted in a mean weight reduction of 8.0% compared with 2.6% with placebo after 56 weeks of treatment.<sup>311</sup> A total of 63.2% of participants in the liraglutide group, compared with 27.1% of participants in the placebo group, lost ≥5% of their body weight.<sup>311</sup> Liraglutide 3 mg also prevented progression of prediabetes to T2D.<sup>75</sup>

In people with obesity and T2D, the SCALE Diabetes trial demonstrated a mean weight change of -5.8% for liraglutide 3.0 mg versus -1.5% with placebo after 56 weeks of treatment.<sup>248</sup> With liraglutide 3.0 mg, 51.8% of individuals achieved ≥5% weight reduction versus 24.0% of individuals with placebo.<sup>248</sup> Liraglutide also resulted in significant improvements in A1C (mean change -1.3% vs -0.3% with placebo), fasting and postprandial glucose levels, and fasting glucagon levels.<sup>248</sup> Weight reduction of ≥4% at

16 weeks best predicted weight reduction after 56 weeks (10.8% vs 3.0% [without T2D] and 8.5% vs 3.1% [T2D]).<sup>312</sup>

The LEADER trial demonstrated that a 1.8-mg dose of liraglutide significantly reduced rates of MACE (CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D and elevated CV risk factors.<sup>252</sup> There is no CVOT with liraglutide in individuals with obesity without T2D.

The main side effects and mitigation strategies of liraglutide are included in the section below as they pertain to the class of GLP-1 RA–based therapies approved by the FDA for treatment of obesity, inclusive of liraglutide, semaglutide, and tirzepatide.

Semaglutide

Semaglutide is a second-generation GLP-1 RA formulated as both a once-weekly subcutaneous (SC) injection ( $t_{1/2}$  183 hours) and as a daily oral tablet. The SC formulation at 2.4 mg per week was approved by the FDA for the treatment of obesity in adults in 2021 and for adolescents ≥12 years of age in 2022,<sup>167,247,313</sup> and for adults with T2D in 2017 at doses of 1 mg and 2 mg SC each week.<sup>314–327</sup> More recently, semaglutide 2.4 mg per week was approved for secondary CV risk reduction.<sup>129,328</sup> Semaglutide SC for obesity is titrated up from a starting or initial dose of 0.25 mg

weekly and titrated monthly as tolerated up to a maximum dose of 2.4 mg weekly for treatment of obesity.<sup>167</sup> The oral formulation of this peptide is approved by the FDA for people with T2D at a dose of 14 mg per day and has been shown to be effective in phase III trials in people with obesity at doses of 25 mg and 50 mg per day.<sup>329</sup>

The Semaglutide Treatment Effect in People with Obesity (STEP 1) trial investigated the efficacy and safety of semaglutide 2.4 mg versus placebo in adults with obesity demonstrating an average percent weight reduction of 16.9% from baseline with 68 weeks of treatment.<sup>167</sup> The STEP 5 trial demonstrated that with a second year of treatment a majority of the weight reduction (16.7%) was maintained.<sup>330</sup> The OASIS-1 investigated the efficacy of daily oral semaglutide at a dose of 50 mg and demonstrated that 68 weeks of therapy resulted in an average percent weight reduction of 17.1%.<sup>331</sup> Currently, higher doses of SC semaglutide (7.2 mg/week) are being tested in phase III trials for individuals with obesity and T2D.<sup>332</sup> In the SUSTAIN-FORTE trial, A1C reduction of 2.2% was demonstrated with SC semaglutide 2.0 mg compared with 1.9% for 1.0 mg in participants with T2D.<sup>333</sup>

Semaglutide had previously been shown to reduce the composite MACE outcome (driven by a reduction in nonfatal stroke) in those with obesity and T2D and with established or at high risk of CVD.<sup>334</sup> The SELECT trial was the first CVOT investigating secondary prevention of CV events in people with established CVD with obesity and without T2D. Treatment with semaglutide 2.4 mg SC resulted in a 20% reduction in 3-point MACE (nonfatal myocardial infarction, nonfatal stroke, and CV death) over a mean exposure duration of 34 months and a mean follow-up of 40 months,<sup>129</sup> garnering semaglutide approval by the FDA for secondary CVD risk reduction. Semaglutide 2.4 mg also has been shown to prevent progression from prediabetes to T2D<sup>243,335</sup> to prevent the decline in renal function in T2D at doses used to treat diabetes,<sup>263</sup> to ameliorate OA<sup>268</sup> and HFpEF,<sup>267</sup> and to improve MASH histology and fibrosis.<sup>101</sup>

The main side effects and mitigation strategies of semaglutide are included in the section below as they pertain to the class of GLP-1 RA–based therapies approved by the FDA for obesity treatment, inclusive of liraglutide, semaglutide, and tirzepatide.

### Tirzepatide

Tirzepatide is a second-generation obesity medication and is the first dual-hormone receptor agonist approved by the FDA; it is a single molecule engineered from the native glucose-dependent insulinotropic polypeptide (GIP) sequence, with action on both the GIP and GLP-1 receptors, thus a dual GIP/GLP-1 RA. As with other nutrient-stimulated hormone-based therapies, tirzepatide impacts weight by acting centrally.

Tirzepatide is formulated as a once-weekly SC injection ( $t_{1/2}$  116.7 hours) titrated up monthly from a starting dose of 2.5 mg weekly to a maximum dose of 15 mg weekly.<sup>336,337</sup> Tirzepatide was approved by the FDA at doses of 5, 10, and 15 mg per week for the treatment of both obesity in 2023 and T2D in 2022.<sup>338</sup> The SURMOUNT trials investigated the efficacy, safety, and tolerability of tirzepatide in obesity.<sup>166,246,339</sup> In the SURMOUNT-1 trial, the highest dose (15 mg) of tirzepatide resulted in an average weight reduction of 22.5% at 72 weeks, with nearly 40% of participants losing  $\geq 25\%$  of their body weight.<sup>166</sup> In addition, SURMOUNT-3 and SURMOUNT-4 demonstrated that combining tirzepatide with intensive lifestyle intervention or continuing treatment for 88 weeks, respectively, resulted in weight reduction up to 26.6% and 26%, respectively, in individuals with obesity.<sup>166,339</sup> As with other

obesity medications, the weight-reduction efficacy is dampened in individuals with T2D compared with individuals with obesity alone. But, notably, in the SURMOUNT-2 trial, tirzepatide reduced weight by an average of 12.8% and 14.7% on 10- and 15-mg doses, respectively, and led to a 2.2% reduction in A1C with nearly half of participants achieving normal A1C values ( $<5.7\%$ ) while experiencing only uncommon episodes of level 2 or no level 3 hypoglycemia.<sup>246</sup> The SURPASS trials investigated the efficacy and safety of tirzepatide in people with T2D.<sup>340–344</sup> Tirzepatide demonstrated an A1C reduction of 1.9% to 2% with  $>87\%$  reaching the A1C target of  $<7\%$ .<sup>344</sup>

In a prespecified post hoc analysis, tirzepatide did not increase the risk of MACE in participants with T2D compared with control individuals; the CVOT in individuals with T2D is ongoing (SURPASS CVOT, NCT04255433).<sup>251,345–347</sup> In addition, SURMOUNT-MMO is an ongoing CVOT investigating both primary and secondary CV risk prevention in individuals with obesity without diabetes (NCT05556512).<sup>348</sup> Tirzepatide has been shown to prevent progression from prediabetes to T2D<sup>244</sup> and to ameliorate OSA,<sup>269</sup> HFpEF,<sup>266</sup> and MASH histology and fibrosis.<sup>102</sup> In December 2024, the FDA approved tirzepatide as the first prescription medicine for the treatment of moderate-to-severe OSA in adults with obesity.<sup>272</sup>

The main side effects of tirzepatide and strategies to mitigate them are included in the section below as they pertain to the class of GLP-1 RA–based therapies inclusive of liraglutide, semaglutide, and tirzepatide.

### Mitigating Side Effects of Nutrient-Stimulated Hormone-Based Therapies

The most common side effects of GLP-1 RA–based medications, such as liraglutide, semaglutide, and tirzepatide, are gastrointestinal in nature, occurring most commonly during dose escalation.<sup>187,286</sup> In people who are naïve to these medications, starting with the lowest dose is essential to prevent clinically significant side effects, and slow dose up-titration is vital in mitigating potential side effects if they occur. In addition, individuals benefit from monitoring which foods may exacerbate side effects (eg, fatty foods), not eating past the point of fullness, and eating smaller amounts at a given time but more frequently if needed. Patients should be counseled that if they discontinue or pause treatment for a length of time, they will need to restart at a low dose and titrate up to enable the body time to acclimate to the medication.<sup>187</sup> GLP-1 RAs also cause a modest increase in heart rate, and those with vomiting or diarrhea should be monitored for dehydration and renal impairment. Therapy is also associated with elevations in lipase and amylase in the absence of pancreatitis. While weight loss from any modality increases risk of gall bladder disease, treatment with GLP-1 RAs appears to augment this risk. The FDA still recommends close monitoring for mood changes, emerging or worsening depression, or suicidal behavior during treatment with GLP-1 RA despite their findings, along with the European Medicines Agency, that evidence is insufficient to support a causal association.<sup>349–351</sup>

### Setmelanotide

Setmelanotide is a melanocortin 4 receptor (MC4R) agonist administered daily by SC injection for the treatment of certain rare genetic disorders of obesity. It received breakthrough drug designation from the FDA in 2020 for chronic weight management in people  $\geq 6$  years of age with obesity caused by POMC, proprotein convertase 1, or leptin receptor deficiency. In June 2022, it was also approved by the FDA for the chronic treatment of Bardet-Biedl

syndrome (BBS) and has efficacy in those with hypothalamic obesity.

Setmelanotide targets the MC4R, which is pivotal in controlling appetite and maintaining energy balance. Individuals with genetic mutations impacting the MC4R pathway often exhibit early onset of severe obesity (before 5 years of age), hyperphagia (uncontrollable hunger), and a positive family history of obesity.

Given the rarity of these genetic mutations, the initial regulatory approval of setmelanotide was based on studies that included 21 participants.<sup>352–355</sup> The findings demonstrated that for the 10 participants with POMC or proprotein convertase 1 deficiency, 8 of 10 patients met the primary outcome of  $\geq 10\%$  weight loss at 1 year; among all enrollees, mean weight reduction was  $-25.6\%$ . For the 11 participants with leptin receptor deficiency, the response to setmelanotide was more variable. Of those 11, only 5 (45%) achieved the primary outcome of  $\geq 10\%$  weight loss at 1 year. For the BBS studies, 16 participants  $\geq 12$  years of age were treated with setmelanotide. Among them, 32.3% experienced a significant reduction of  $\geq 10\%$  in body weight after 52 weeks. Furthermore, quality of life studies involving 20 participants with BBS revealed meaningful improvements across various health-related quality of life measures after 1 year of setmelanotide treatment.<sup>356</sup> People with hypothalamic obesity have also been shown to benefit from treatment with setmelanotide.<sup>357</sup>

The most common adverse events of setmelanotide are injection site reactions, skin hyperpigmentation (which improved after stopping the medication), nausea, vomiting, and diarrhea. Other side effects include spontaneous penile erections and spontaneous female arousal, depression, and suicidal thoughts.

#### Cellulose and Citric Acid Hydrogel

The combination product of cellulose and citric acid hydrogel differs from other available products because it is not a medication but rather a matrix that is not absorbed, occupying volume in the stomach with the goal to promote fullness. It is considered a medical device with FDA clearance for weight management. In the GLOW and GLOW-EX studies, 59% of participants achieved 5% weight reduction.<sup>358</sup> This product should be avoided in those with a history of gastrointestinal disorders and may impact the absorption of other medications. Plenity was discontinued by the manufacturer in 2023 for financial reasons. Another hydrogel, Epitomee, is approved for treating people with obesity over the BMI range of 25.0 kg/m<sup>2</sup> to 40.0 kg/m<sup>2</sup> and produced a 4.5% weight loss in a clinical trial after 12 weeks with reductions in BP and triglycerides.<sup>359,360</sup>

#### Online Prescriptions for Obesity Medications and Compounded, Nutrient-Stimulated, Hormone-Based Peptides

It should be clear that online prescriptions for obesity medications, unless accompanied by clinical evaluation by a health care professional, would not provide for assessment of ORCD. Without the clinical component of diagnosis and the evaluation for ORCD, complication-centric care is not possible, and the principles defining quality care for people with ABCD in [Algorithm 1](#) could not be operative. Furthermore, people with ABCD require long-term follow-up for evaluating response to therapy regarding ORCD and the maintenance of health benefits. Individuals should also be supported and managed to assure adequate nutrition, mitigation of side effects, avoidance of unhealthy excessive weight loss and inadequate nutrition (particularly on second-generation obesity medications), and establishment of safe long-term maintenance therapy which may differ from interventions first used for active weight loss. There are opportunities for telemedicine and telehealth strategies in the care of people with ABCD. Whether follow-

up involves in-person visits or telehealth, the involvement of trained health care professionals is required to achieve these aspects of care. Online prescription of obesity medications per se, operating without involvement of health care professions for initial evaluation and follow-up, represents substandard care and places individuals at risk.

Compounded alternatives to FDA-approved semaglutide and tirzepatide are often dispensed via online pharmacies. AACE advises against the use of these agents. Several factors led to the demand for compounded medications, including the unprecedented efficacy of semaglutide and tirzepatide combined with the high cost, inadequate insurance coverage, and limited supply of the preparations approved by the FDA.

Both tirzepatide and semaglutide have periodically been in shortage because of the imbalance between supply and demand. Compounders may prepare compounded versions of a drug on FDA's list of drug shortages if the compounded drug meets certain conditions detailed in federal law. Compounded drugs, however, are not approved by the FDA; thus, without verification of safety, effectiveness, or quality before they are marketed, they pose a higher risk to individuals than drugs approved by the FDA. An analysis of compounded preparations has demonstrated inaccurately labeled concentrations, impurities, other high molecular weight peptides, trace metals, residual solvents, and neopeptides (compounded semaglutide is usually manufactured using peptide synthesis and not by recombinant DNA) with potential immunogenicity.<sup>361</sup> The FDA has recommended caution over the use of compounded semaglutide and tirzepatide because of overdosing that has led to hospitalizations.<sup>362</sup> Involved pharmaceutical companies have asked the FDA to place tirzepatide and semaglutide on its demonstrable difficulties for compounding lists, and this designation has recently been approved. Drug products or categories that present "demonstrable difficulties for compounding" under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act would prohibit compounding those medications.

#### Conclusions

Obesity is a chronic, heterogeneous, neuroendocrine, progressive and/or relapsing disease impacted by the obesogenic environment and genetic susceptibility factors resulting in excess or abnormally distributed adiposity which impairs overall health. This algorithm guides clinicians in the decision-making process with their patients for the medical treatment of ABCD using a complication-centric approach and provides supportive guidance for personalized lifestyle and behavioral interventions. Anthropometric and clinical evaluation provides the basis for diagnosis and disease staging, which informs decisions regarding therapy intensity and the setting of individualized therapeutic goals. The evaluation requires a general medical and obesity-focused history, obesity-oriented review of systems, a physical examination, and key laboratory testing by a trained health care professional. In addition, an individualized care plan requires patient engagement in decision making and consideration of bias and stigmatization, psychological disorders, and social determinants of health. Clinical goals extend beyond weight reduction and maintenance to a primary focus on amelioration of ORCD, improved health outcomes, and a better quality of life consistent with a complication-centric approach to care.

Lifestyle interventions remain an important component for optimizing health in individuals with ABCD. This includes personalized medical nutrition therapy, prescribed physical activity, and behavioral interventions to help optimize healthful eating and integrate movement into daily life. It is key that individuals with ABCD incorporate these lifestyle and behavioral

2025

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY

# AACE ALGORITHM

## FOR THE EVALUATION AND TREATMENT OF ADULTS WITH OBESITY/ADIPOSIY-BASED CHRONIC DISEASE

1373

### Algorithm Title Page

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.





# TABLE OF CONTENTS

|     |                                                                                        |
|-----|----------------------------------------------------------------------------------------|
| 1.  | Principles of Person-Centered and Complication-Centric Management of Obesity/ABCD      |
| 2.  | Care Model for People with Obesity/ABCD: Screening and Diagnosis                       |
| 3.  | Diagnosis: Anthropometric Component                                                    |
| 4.  | Diagnosis: Clinical Component                                                          |
| 5.  | Individualized Treatment Plan, Therapeutic Goals, and Follow-Up                        |
| 6.  | Response to Therapy and Weight-Loss Targets for People with ABCD                       |
| 7.  | Behavioral/Lifestyle Therapy for People with Obesity/ABCD                              |
| 8.  | Hierarchies of Preferred Medications for Complication-Centric Care of People with ABCD |
| 9.  | Lower-Cost Pharmacologic Step Therapy for ABCD                                         |
| 10. | Medications for Obesity: Individualization of Therapy                                  |
| 11. | Medications for Obesity Approved by the U.S. Food and Drug Administration              |

Abbreviations: **ABCD**, adiposity-based chronic disease; **FDA**, U.S. Food and Drug Administration

## Algorithm Table of Contents

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.  
Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



## PRINCIPLES OF PERSON-CENTERED AND COMPLICATION-CENTRIC MANAGEMENT OF OBESITY/ABCD

|    |                                                                                                                                                                                                                                                                                                                                           |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Emphasize whole-person health and de-emphasize BMI and weight-centric approaches in the treatment of individuals with obesity/ABCD.                                                                                                                                                                                                       |
| 2. | People with obesity/ABCD should be evaluated by an empathetic trained health care professional to include both the anthropometric and clinical components of the diagnosis and should be followed long-term by a health care professional who will manage weight loss and assure that treatment goals for optimizing health are achieved. |
| 3. | For the anthropometric component of the diagnosis, obesity is evaluated using BMI with clinical confirmation of excess adiposity, waist circumference, waist-to-height ratio, and assessment of body composition when clinically needed.                                                                                                  |
| 4. | For the clinical component of the diagnosis and disease staging of ABCD, assess the risk, presence, and severity of ORCD. Include internalized weight bias and impact of stigmatization as part of clinical staging.                                                                                                                      |
| 5. | Involve the individual in shared decision-making to determine personalized health goals while targeting sufficient weight loss to achieve clinical treatment goals for health.                                                                                                                                                            |
| 6. | Develop treatment plans involving lifestyle, pharmacologic, and surgical options using an individualized approach that considers complications and their severity, patient preferences, social determinants of health, psychological disorders, and access to care.                                                                       |
| 7. | The goals of therapy are to improve health and the quality of life by preventing or treating ORCD, not solely defined by the loss of a specific amount of weight.                                                                                                                                                                         |
| 8. | Therapy, beyond behavioral/lifestyle alone, should be considered at all stages of ABCD (stages 1, 2, or 3) when needed to improve the health of patients.                                                                                                                                                                                 |
| 9. | Implement a plan for long-term follow-up with each patient to monitor maintenance of healthy goals, clinical outcomes, and treatment modifications as needed.                                                                                                                                                                             |

Abbreviations: **ABCD**, adiposity-based chronic disease; **BMI**, body mass index; **ORCD**, obesity-related complications and diseases


### Algorithm Figure 1 - Guiding Principles

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



# CARE MODEL FOR PEOPLE WITH OBESITY/ABCD: SCREENING AND DIAGNOSIS



Abbreviations: **ABCD**, adiposity-based chronic disease; **BMI**, body mass index; **ORCD**, obesity-related complications and diseases

**Algorithm Figure 2 - Screening and Diagnosis**

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.

## DIAGNOSIS: ANTHROPOMETRIC COMPONENT

### Anthropometric Screening & Classification

#### Measure BMI

Clinically examine and confirm excess adiposity



#### Measure Waist Circumference

for BMI <35.0 kg/m<sup>2</sup>, and

#### Calculate Waist-to-Height Ratio

for classifying abdominal obesity and cardiometabolic risk

| Class                   | WHO BMI Classification         |
|-------------------------|--------------------------------|
| Overweight <sup>a</sup> | 25.0 – 29.9 kg/m <sup>2</sup>  |
| Class I Obesity*        | 30.0 – 34.9 kg/m <sup>2</sup>  |
| Class II Obesity        | ≥35.0 – 39.9 kg/m <sup>2</sup> |
| Class III Obesity       | ≥40.0 kg/m <sup>2</sup>        |

<sup>a</sup> In the Asia-Pacific region, the BMI threshold for obesity is generally considered to be ≥25 kg/m<sup>2</sup> and for overweight 23 kg/m<sup>2</sup> to 24.9 kg/m<sup>2</sup>. See text for additional information.



#### Assess Body Composition

Using, for example, bioelectrical impedance analysis or DXA if clinically needed and available

| International Diabetes Federation<br>Waist Circumference Criteria<br>for Cardiometabolic Risk <sup>b</sup> |        |                                     | National Institute for Health<br>and Care Excellence, and<br>World Health Organization |
|------------------------------------------------------------------------------------------------------------|--------|-------------------------------------|----------------------------------------------------------------------------------------|
| Region/Ethnic<br>Background <sup>c</sup>                                                                   | Sex    | Waist<br>Circumference <sup>d</sup> | Waist-to-Height Ratio                                                                  |
| Europe, Sub-Saharan<br>Africa, and Middle East                                                             | Male   | ≥94 cm                              | ≥0.5                                                                                   |
|                                                                                                            | Female | ≥80 cm                              | ≥0.5                                                                                   |
| United States & Canada                                                                                     | Male   | ≥102 cm                             | ≥0.5                                                                                   |
|                                                                                                            | Female | ≥88 cm                              | ≥0.5                                                                                   |
| Asia, South &<br>Central America                                                                           | Male   | ≥90 cm                              | ≥0.5                                                                                   |
|                                                                                                            | Female | ≥80 cm                              | ≥0.5                                                                                   |

<sup>b</sup> Darbandi M et al. Discriminatory Capacity of Anthropometric Indices for Cardiovascular Disease in Adults: A Systematic Review and Meta-Analysis. Prev Chronic Dis. 2020 Oct 22;17:E131.

<sup>c</sup> See text for additional information.

<sup>d</sup> Increasing waist circumference correlates with increased severity of obesity.

Obesity: Identification, assessment and management. NICE Guideline, No. 189.

London: National Institute for Health and Care Excellence (NICE); 2023 Jul 26. Recommendations 1.2.11 and 1.2.12

Abbreviations: **BMI**, body mass index; **DXA**, dual-energy X-ray absorptiometry; **WHO**, World Health Organization

#### Algorithm Figure 3 - Diagnosis: Anthropometric Component


COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



## DIAGNOSIS: CLINICAL COMPONENT

### Adiposity-Based Chronic Disease (ABCD) / Obesity-Related Diseases and Complications (ORCD)




<sup>a</sup> The degree of severity for ORCD is based on clinical judgment, incorporating findings from physical examination, laboratory testing, and/or other diagnostic procedures, as well as a person's symptomatology, in ways that apply to each individual complication.

#### Algorithm Figure 4 - Diagnosis: Clinical Component

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.

# INDIVIDUALIZED TREATMENT PLAN, THERAPEUTIC GOALS, AND FOLLOW-UP



<sup>a</sup> The degree of severity for ORCD is based on clinical judgment, incorporating findings from physical examination, laboratory testing, and/or other diagnostic procedures, as well as a person's symptomatology, in ways that apply to each individual complication.

Abbreviations: **ABCD**, adiposity-based chronic disease; **ORCD**, obesity-related complications and diseases


**Algorithm Figure 5 - Treatment Plan, Therapeutic Goals, and Follow-Up**

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.

# RESPONSE TO THERAPY AND WEIGHT-LOSS TARGETS FOR PEOPLE WITH ABCD

## Weight Reduction Necessary for Effective Treatment of ORCD



Re-evaluate and intensify lifestyle, medical, and/or surgical therapy as needed to achieve clinical goals

Consider de-escalation of specific therapies used to treat ORCD as clinically directed (e.g., T2D, HTN, HLD, OSA)

Long-term weight-maintenance plan

Abbreviations: **ABCD**, adiposity-based chronic disease; **BMI**, body mass index; **CVD**, cardiovascular disease; **GERD**, gastroesophageal reflux disease; **HLD**, hyperlipidemia; **HTN**, hypertension; **MASH**, metabolic dysfunction-associated steatohepatitis; **MASLD**, metabolic dysfunction-associated steatotic liver disease; **OA**, osteoarthritis; **ORCD**, obesity-related complications and diseases; **OSA**, obstructive sleep apnea; **PCOS**, polycystic ovary syndrome; **T2D**, type 2 diabetes

Algorithm Figure 6 - Response to Therapy and Weight-Loss Targets

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.

## BEHAVIORAL/LIFESTYLE THERAPY FOR PEOPLE WITH OBESITY/ABCD

Consider social determinants of health, including access to care and specialists, nutritious food, safe spaces for physical activity, and sleep when developing a treatment plan.

### NUTRITION

Focus on a reduced-calorie diet while maintaining diet quality.

- Adopt healthful meal patterns (eg, Mediterranean diet).
- Prioritize minimally processed, nutrient-dense foods.
- Limit energy-dense foods and beverages.
- Ensure adequate nutrient intake of protein, fiber, iron, calcium, and other micronutrients with significant weight loss.

Individualized energy plans may include:

- Macronutrient-based strategies
- Meal replacements
- Strategic fasting
- Personalized calorie targets

*Consider referral to a registered dietitian. Combine evidence-based dietary approaches to suit individual and cultural preferences.*


### SLEEP

Screen for sleep disorders.

Promote good sleep hygiene.

Optimize sleep quality and duration.

*Refer for polysomnography or sleep medicine evaluation if needed.*



### PHYSICAL ACTIVITY

Tailor to patient preferences and functional ability.

Incorporate:

- Aerobic activity
- Resistance training<sup>a</sup>
- Reduced sedentary behavior

Gradually increase intensity and volume as tolerated.

*Refer to an exercise specialist if needed.*

<sup>a</sup> Resistance training helps preserve lean mass during significant weight loss.

### BEHAVIORAL THERAPY

Screen for anxiety, depression, eating disorders, and internalized weight bias.

Support behavioral adherence with:

- Goal setting, self-monitoring, and problem-solving
- Cognitive behavioral therapy
- Stress reduction techniques

*Refer for psychological testing or behavioral health support as needed.*

Abbreviation: **ABCD**, adiposity-based chronic disease


Algorithm Figure 7 - Behavioral/Lifestyle Therapy

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.



# HIERARCHIES OF PREFERRED MEDICATIONS FOR COMPLICATION-CENTRIC CARE OF PEOPLE WITH ABCD




Abbreviations: **ABCD**, adiposity-based chronic disease; **HFpEF**, heart failure with preserved ejection fraction; **MACE**, major adverse cardiac events; **MASH**, metabolic dysfunction-associated steatohepatitis; **T2D**, type 2 diabetes

Algorithm Figure 8 - Preferred Medications Hierarchies

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.

# LOWER-COST PHARMACOLOGIC STEP THERAPY FOR ABCD



<sup>a</sup> 1st-generation obesity medications: phentermine, phentermine/topiramate ER, naltrexone/bupropion ER, liraglutide

<sup>b</sup> 2nd-generation more effective obesity medications: semaglutide, tirzepatide

Abbreviations: **ABCD**, adiposity-based chronic disease; **ER**, extended release

**Algorithm Figure 9 - Lower-Cost Pharmacologic Step Therapy**

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit [doi.org/10.1016/j.eprac.2025.07.017](https://doi.org/10.1016/j.eprac.2025.07.017) to request copyright permission.

# MEDICATIONS FOR OBESITY: INDIVIDUALIZATION OF THERAPY<sup>a</sup>

KEY:   Preferred (evidence of benefit)   Insufficient evidence to prefer   Monitoring indicated   Contraindicated (evidence of risk/harm)

| OBESITY-RELATED CONDITION | ORLISTAT                        | PHENTERMINE                         | PHENTERMINE/<br>TOPIRAMATE ER                                      | NALTREXONE ER/<br>BUPROPION ER      | LIRAGLUTIDE                                         | SEMAGLUTIDE                                         | TIRZEPATIDE                                         |
|---------------------------|---------------------------------|-------------------------------------|--------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| DIABETES PREVENTION       | Benefit via weight reduction    |                                     | Benefit via weight reduction                                       |                                     | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    |
| TYPE 2 DIABETES           | Benefit via weight reduction    |                                     | Benefit via weight reduction                                       | Benefit via weight reduction        | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    | Benefit via weight reduction and incretin effect    |
| HYPERTENSION              | Benefit via weight reduction    | Monitor heart rate, BP              | Monitor heart rate, BP; BP benefit observed in trials <sup>b</sup> | Monitor heart rate, BP              | BP benefit observed in trials; Monitor heart rate   | BP benefit observed in trials; Monitor heart rate   | BP benefit observed in trials; Monitor heart rate   |
|                           |                                 | Contraindicated in uncontrolled HTN |                                                                    | Contraindicated in uncontrolled HTN |                                                     |                                                     |                                                     |
| ASCVD                     |                                 | Contraindicated                     | Use with caution; Monitor heart rate, BP                           | Monitor heart rate, BP              | Demonstrated prevention of ASCVD in T2D             | Demonstrated prevention of ASCVD                    | Evidence in T2D and obesity pending                 |
| MASLD                     |                                 |                                     |                                                                    |                                     | Benefit observed in trials                          | Benefit observed in trials                          | Benefit observed in trials                          |
| DEPRESSION                |                                 |                                     | Appropriate monitoring                                             | Appropriate monitoring              | Appropriate monitoring                              | Appropriate monitoring                              | Appropriate monitoring                              |
| ANXIETY                   |                                 | Appropriate monitoring              | Appropriate monitoring                                             | Appropriate monitoring              |                                                     |                                                     |                                                     |
| CHRONIC KIDNEY DISEASE    | Monitor for oxalate nephropathy |                                     | Do not exceed 7.5 mg/46 mg per day                                 | Do not exceed 8 mg/90mg twice a day | Benefit in T2D; Avoid vomiting and volume depletion | Benefit in T2D; Avoid vomiting and volume depletion | Benefit in T2D; Avoid vomiting and volume depletion |
| SEVERE KIDNEY IMPAIRMENT  | Monitor for oxalate nephropathy | Urinary clearance of drug           | Urinary clearance of drug                                          | Urinary clearance of drug           | Avoid vomiting and volume depletion                 | Avoid vomiting and volume depletion                 | Avoid vomiting and volume depletion                 |
| NEPHROLITHIASIS           | Calcium oxalate stones          |                                     | Calcium phosphate stones                                           |                                     |                                                     |                                                     |                                                     |
| HEPATOBIILIARY IMPAIRMENT | Monitor for cholelithiasis      | Do not exceed 8 mg per day          | Do not exceed 7.5 mg/46 mg per day                                 | Do not exceed 8 mg/90 mg daily      | Monitor for cholelithiasis                          | Monitor for cholelithiasis                          | Monitor for cholelithiasis                          |
| SEVERE HEPATIC IMPAIRMENT | Not recommended                 |                                     |                                                                    |                                     |                                                     |                                                     |                                                     |

<sup>a</sup> All medications are contraindicated in pregnancy and breastfeeding. <sup>b</sup> Blood pressures are significantly decreased in clinical trials.

Abbreviations: **ASCVD**, atherosclerotic cardiovascular disease; **BP**, blood pressure; **ER**, extended release; **HTN**, hypertension; **T2D**, type 2 diabetes

**Algorithm Figure 10 - Medications for Obesity: Individualization of Therapy**

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.



# MEDICATIONS FOR OBESITY APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION<sup>a,b</sup>

|                                                                | ORLISTAT                                                                                                                                       | PHENTERMINE <sup>c</sup>                                                                                                                                       | PHENTERMINE/<br>TOPIRAMATE ER                                                                                                                                                                            | NALTREXONE ER/<br>BUPROPION ER                                                                                                                                                                                                           | LIRAGLUTIDE                                                                                                                                                                             | SEMAGLUTIDE                                                                                                                                                                                    | TIRZEPATIDE                                                                                                                                                                                                       |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CLASS/MECHANISM OF ACTION                                      | Lipase Inhibitor                                                                                                                               | NE-Releasing Agent                                                                                                                                             | NE-Releasing Agent<br>GABA Receptor Modulation                                                                                                                                                           | Opioid-Receptor Antagonist<br>DA-NE Reuptake Inhibitor                                                                                                                                                                                   | GLP-1 RA                                                                                                                                                                                | GLP-1 RA                                                                                                                                                                                       | GIP/GLP-1 RA                                                                                                                                                                                                      |
| AGE                                                            | ≥12 years <sup>d</sup>                                                                                                                         | >16 years                                                                                                                                                      | ≥12 years                                                                                                                                                                                                | ≥18 years <sup>d</sup>                                                                                                                                                                                                                   | ≥12 years <sup>e</sup>                                                                                                                                                                  | ≥12 years <sup>e</sup>                                                                                                                                                                         | ≥18 years <sup>d</sup>                                                                                                                                                                                            |
| DELIVERY                                                       | Oral                                                                                                                                           | Oral                                                                                                                                                           | Oral                                                                                                                                                                                                     | Oral                                                                                                                                                                                                                                     | Subcutaneous Injection                                                                                                                                                                  | Subcutaneous Injection                                                                                                                                                                         | Subcutaneous Injection                                                                                                                                                                                            |
| STARTING DOSE                                                  | 60 mg 3 times/day AC                                                                                                                           | 8 mg or 15 mg QAM                                                                                                                                              | 3.75 mg/23 mg QAM                                                                                                                                                                                        | 8 mg/90 mg QAM                                                                                                                                                                                                                           | 0.6 mg QD                                                                                                                                                                               | 0.25 mg QWK                                                                                                                                                                                    | 2.5 mg QWK                                                                                                                                                                                                        |
| DOSE ESCALATION                                                | Titrate up to needed dose<br><br>Slow dose titration if side effects occur<br><br>Formulations:<br>60 mg cap<br>120 mg cap                     | Titrate up to needed dose<br><br>Slow down dose titration if side effects occur<br><br>Formulations:<br>8 mg tab<br>15 mg cap<br>37.5 mg tab                   | Titrate up bi-weekly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>3.75 mg/23 mg QAM x 2 wk<br>7.5 mg/ 46 mg QAM x 12 wk<br>11.25 mg / 69 mg QAM x 2 wk<br>15 mg/92 mg QAM | Titrate up weekly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>8 mg/90 mg QAM x 1wk<br>8 mg/90 mg twice daily x 1 wk<br>16 mg/90 mg QAM and<br>8 mg/90 mg QPM x 1 wk<br>16 mg/90 mg twice daily           | Titrate up weekly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>0.6 mg QD x 1 wk<br>1.2 mg QD x 1 wk<br>1.8 mg QD x 1 wk<br>2.4 mg QD x 1 wk<br>3.0 mg QD | Titrate up monthly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>0.25 mg QWK x 4 wk<br>0.5 mg QWK x 4 wk<br>1.0 mg QWK x 4 wk<br>1.7 mg QWK x 4 wk<br>2.4 mg QWK | Titrate up monthly to needed dose<br><br>Slow down dose titration if side effects occur<br><br>2.5 mg QWK x 4 wk<br>5.0 mg QWK x 4 wk<br>7.5 mg QWK x 4 wk<br>10 mg QWK x 4 wk<br>12.5 mg QWK x 4 wk<br>15 mg QWK |
| MAXIMUM DOSE                                                   | 120 mg 3 times/day AC                                                                                                                          | 37.5 mg QAM <sup>f</sup>                                                                                                                                       | 15 mg/92 mg QD                                                                                                                                                                                           | 16 mg/180 mg twice daily                                                                                                                                                                                                                 | 3.0 mg QD                                                                                                                                                                               | 2.4 mg QWK                                                                                                                                                                                     | 15 mg QWK                                                                                                                                                                                                         |
| WEIGHT REDUCTION <sup>g</sup>                                  | 4%<br>(52 weeks)                                                                                                                               | 5%-6%<br>(28 weeks)                                                                                                                                            | 9.6%-9.9%<br>(52 weeks) dose dependent                                                                                                                                                                   | 4.2%-5.2%<br>(52 weeks)                                                                                                                                                                                                                  | 9.2%<br>(56 weeks)                                                                                                                                                                      | 16.9%<br>(68 weeks)                                                                                                                                                                            | 22.5%<br>(72 weeks)                                                                                                                                                                                               |
| POTENTIAL SIDE EFFECTS <sup>h</sup>                            | Flatulence<br>Fecal Urgency<br>Oily Stools<br>Fat-Soluble Vitamin and Drug Malabsorption<br>Potential Drug-Drug Interactions                   | Restlessness<br>Insomnia<br>Headache<br>Dry Mouth<br>Tachycardia<br>BP Elevation                                                                               | Paresthesia, Dizziness<br>Dysgeusia, Insomnia<br>Constipation, Dry Mouth<br>Fatigue<br>Blurred Vision<br>Mental Clouding<br>Mood Changes                                                                 | Nausea, Constipation<br>Headache<br>Vomiting<br>Dizziness<br>Insomnia<br>Dry Mouth, Diarrhea Anxiety                                                                                                                                     | Nausea<br>Diarrhea<br>Constipation<br>Dyspepsia<br>Vomiting<br>Abdominal Pain<br>GERD                                                                                                   | Nausea, Diarrhea<br>Constipation<br>Dyspepsia<br>Vomiting<br>Abdominal Pain<br>Headache<br>Fatigue                                                                                             | Nausea, Diarrhea<br>Constipation<br>Dyspepsia<br>Vomiting<br>Abdominal Pain<br>Headache<br>Fatigue                                                                                                                |
| CAUTIONS, RELATIVE AND ABSOLUTE CONTRAINDICATIONS <sup>i</sup> | Cholestasis<br>Chronic Malabsorption Syndrome<br>Nephrolithiasis<br>Vitamin Malabsorption<br>Encourage Supplementation<br>Potential for Misuse | CAD, CVA, Arrhythmias, CHF, Uncontrolled HTN <sup>k</sup><br>Hyperthyroidism<br>Agitated States<br>History of Drug Abuse<br>MAOI Use<br>Angle-Closure Glaucoma | MAOI<br>Hyperthyroidism<br>Angle-Closure Glaucoma<br>Monitor for Increased Heart Rate<br>Nephrolithiasis<br>Metabolic Acidosis <sup>c</sup><br>Monitor for Worsening Anxiety or Depression <sup>c</sup>  | Seizure Disorder<br>Uncontrolled HTN<br>Chronic Opioid Use<br>Anorexia Nervosa<br>Bulimia Nervosa<br>MAOI Use<br>Abrupt Drug or Alcohol Withdrawal<br>Angle-Closure Glaucoma<br>Monitor for Worsening Anxiety or Depression <sup>c</sup> | History or Family History<br>MTC/MEN2<br>Gallbladder Disease<br>Pancreatitis<br>Increased Heart Rate                                                                                    | History or Family History<br>MTC/MEN2<br>Gallbladder Disease<br>Pancreatitis<br>Diabetic Retinopathy <sup>j</sup>                                                                              | History or Family History<br>MTC/MEN2<br>Gallbladder Disease<br>Diabetic Retinopathy <sup>j</sup>                                                                                                                 |
| ACCESS/COST                                                    | \$\$                                                                                                                                           | \$                                                                                                                                                             | \$\$                                                                                                                                                                                                     | \$\$                                                                                                                                                                                                                                     | \$\$\$                                                                                                                                                                                  | \$\$\$\$                                                                                                                                                                                       | \$\$\$\$                                                                                                                                                                                                          |

<sup>a</sup>Monogenic obesity treatment, devices for weight reduction, and setmelanotide can be found in narrative. <sup>b</sup>FDA-approved for CWM. <sup>c</sup>This class of medications includes diethylpropion (or amfepramone), phendimetrazine, and benzphetamine. <sup>d</sup>EMA approved for age 18 years and above for CWM. <sup>e</sup>EMA approved for age 12 years and above for CWM. <sup>f</sup>Maximum dose allowed for phentermine; however, many patients will see results on 8 mg 3 times a day which is also considered a maintenance dose in patients with diabetes and obesity. <sup>g</sup>Percent body weight reduction in treatment in phase III trial. <sup>h</sup>Complications requiring caution or monitoring in order of observed frequency. <sup>i</sup>All FDA-approved medications for obesity are contraindicated in individuals who are pregnant or breastfeeding; effective birth control should be recommended/prescribed. A negative pregnancy test is recommended before initiating, with monthly monitoring. <sup>j</sup>In patients with T2D and obesity. <sup>k</sup>Blood pressures are significantly decreased in clinical trials for phentermine/topiramate ER.

Abbreviations: AC, before meals; BP, blood pressure; CAD, coronary artery disease; CHF, congestive heart failure; CVA, cerebrovascular accident; CWM, chronic weight management; DA, dopamine; EMA, European Medicines Agency; ER, extended release; FDA, U.S. Food and Drug Administration; GERD, gastroesophageal reflux disease; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HTN, hypertension; MAOI, monoamine oxidase inhibitors; MEN2, multiple endocrine neoplasia, type 2; MTC, medullary thyroid cancer; NE, norepinephrine; QAM, every morning; QD, every day; QPM, every afternoon or evening; QWK, every week; wk, week(s)

## Algorithm Figure 11 - FDA-Approved Medications for Obesity: Prescribing Information

COPYRIGHT © 2025 AACE. May not be reproduced in any form without express written permission from Elsevier on behalf of AACE.

Visit doi.org/10.1016/j.eprac.2025.07.017 to request copyright permission.





efforts alongside initiation and continuation of pharmacotherapeutic interventions for improvement of overall health.

Medications have variable mechanisms of actions, side effects, and clinical outcomes. Shared decision making should be used to individualize care, matching a person with the pharmacotherapeutic interventions that may optimally treat their disease, improve quality of life, and treat or prevent ORCD. The algorithm for the first time establishes hierarchies of preferred medications in complication-centric care based on evidence for amelioration of specific ORCD. Importantly, as for any complex, chronic disease, it is critical to provide lifelong care, adjusting obesity treatment interventions to the needs of each person with the goal of optimizing overall health over their lifetime.

## Review Process

Drafts of this consensus statement were reviewed and approved by all task force members, the AACE Clinical Practice Guidelines Oversight Committee, the AACE Board of Directors, and peer reviewers for *Endocrine Practice*.

## Disclosures

The task force was empaneled in accordance with the 2019 AACE Conflicts of Interest Policy. Disclosures were updated and reviewed annually at a minimum and as necessary to maintain accuracy. See [Appendix A](#) for a full list of disclosures.

## Acknowledgments

The task force is grateful for the invaluable contributions of the authors of the 2016 guideline and algorithm who laid the foundation for this 2025 update: Elise M. Brett, Alan J. Garber, W. Timothy Garvey, Daniel L. Hurley, Ania M. Jastreboff, Jeffrey I. Mechanick, Karl Nadolsky, Rachel Pessah-Pollack, and Raymond Plodkowski.<sup>5</sup>

## Funding

The algorithm for the evaluation and treatment of adults with obesity/ABCD was developed with financial support from AACE. AACE received no outside funding for the development of this guidance document. All members who served on this AACE task force completed the work electronically and met via video conferences. Volunteer authors received no remuneration for their participation in the development of this guidance document.

## Panel Composition

This consensus statement was developed by a task force of credentialed medical professionals in the fields of endocrinology, obesity medicine, and primary care, and included a pharmacist and a registered dietician who are current AACE members in good standing.

## Document Retirement Date: November 2030

AACE reviews and considers updating or retiring its guidance documents every 5 years following publication or sooner if significant scientific developments or change in public policy occurs.

## References

1. American Association of Clinical Endocrinologists/American College of Endocrinology. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity. *Endocr Pract.* 1997;3(3):162–208.
2. American Association of Clinical Endocrinologists/American College of Endocrinology. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity. *Endocr Pract.* 1998;4(5):297–330.
3. Mechanick JL, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. *Endocr Pract.* 2012;18(5):642–648. <https://doi.org/10.4158/ep12160.Ps>.
4. Garvey WT, Garber AJ, Mechanick JL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. *Endocr Pract.* 2014;20(9):977–989. <https://doi.org/10.4158/ep14280.Ps>.
5. Garvey WT, Mechanick JL, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract.* 2016;22(Suppl 3):1–203. <https://doi.org/10.4158/ep161365.Gl>.
6. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. *Int J Obes (Lond).* 2009;33(3):289–295. <https://doi.org/10.1038/ijo.2009.2>.
7. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. *CMAJ.* 2011;183(14):E1059–E1066. <https://doi.org/10.1503/cmaj.110387>.
8. Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. *Obesity (Silver Spring).* 2014;22(1):110–118. <https://doi.org/10.1002/oby.20585>.
9. Mechanick JL, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement. *Endocr Pract.* 2017;23(3):372–378. <https://doi.org/10.4158/ep161688.Ps>.
10. Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. *Obes Facts.* 2019;12(2):131–136. <https://doi.org/10.1159/000497124>.
11. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. *Lancet Diabetes Endocrinol.* 2025;13(3):221–262. [https://doi.org/10.1016/s2213-8587\(24\)00316-4](https://doi.org/10.1016/s2213-8587(24)00316-4).
12. Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev.* 2017;18(7):715–723. <https://doi.org/10.1111/obr.12551>.
13. Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: the Obesity Society 2018 position statement. *Obesity (Silver Spring).* 2019;27(1):7–9. <https://doi.org/10.1002/oby.22378>.
14. STOP Obesity Alliance. Consensus statement on obesity as a disease. <https://stoppublichealth.gwu.edu/obesity-statement>. Accessed August 11, 2023.
15. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: an Endocrine Society scientific statement. *Endocr Rev.* 2017;38(4):267–296. <https://doi.org/10.1210/er.2017-00111>.
16. Bray GA, Bouchard C. The biology of human overfeeding: a systematic review. *Obes Rev.* 2020;21(9):e13040. <https://doi.org/10.1111/obr.13040>.
17. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. *Nat Rev Genet.* 2022;23(2):120–133. <https://doi.org/10.1038/s41576-021-00414-z>.
18. Speakman JR, Levitsky DA, Allison DB, et al. Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity. *Dis Model Mech.* 2011;4(6):733–745. <https://doi.org/10.1242/dmm.008698>.
19. Garvey WT. Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications. *Endocr Pract.* 2022;28(2):214–222. <https://doi.org/10.1016/j.eprac.2021.11.082>.
20. Speakman JR. Why lipostatic set point systems are unlikely to evolve. *Mol Metab.* 2018;7:147–154. <https://doi.org/10.1016/j.molmet.2017.10.007>.
21. Laughlin MR, Osganian SK, Yanovski SZ, Lynch CJ. Physiology of the weight-reduced state: a report from a National Institute of Diabetes and Digestive and Kidney Diseases workshop. *Obesity (Silver Spring).* 2021;29(Suppl 1):S5–S8. <https://doi.org/10.1002/oby.23079>.
22. Jais A, Brüning JC. Arcuate nucleus-dependent regulation of metabolism-pathways to obesity and diabetes mellitus. *Endocr Rev.* 2022;43(2):314–328. <https://doi.org/10.1210/endrev/bnab025>.
23. Magkos F, Sørensen TIA, Raubenheimer D, et al. On the pathogenesis of obesity: causal models and missing pieces of the puzzle. *Nat Metab.* 2024;6(10):1856–1865. <https://doi.org/10.1038/s42255-024-01106-8>.
24. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. *Nat Med.* 2020;26(4):485–497. <https://doi.org/10.1038/s41591-020-0803-x>.
25. Busetto L, Dicker D, Frühbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. *Nat Med.* 2024;30(9):2395–2399. <https://doi.org/10.1038/s41591-024-03095-3>.
26. Nadolsky K, Addison B, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: addressing stigma and bias in the diagnosis and management of patients with obesity/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severity. *Endocr Pract.* 2023;29(6):417–427. <https://doi.org/10.1016/j.eprac.2023.03.272>.
27. Garvey WT. New horizons. A new paradigm for treating to target with second-generation obesity medications. *J Clin Endocrinol Metab.* 2022;107(4):e1339–e1347. <https://doi.org/10.1210/clinem/dgab848>.
28. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes

- management algorithm - 2023 update. *Endocr Pract.* 2023;29(5):305–340. <https://doi.org/10.1016/j.eprac.2023.02.001>.
29. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser.* 2000;894:i–xii, 1–253.
  30. Misra A. Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement. *Diabetes Technol Ther.* 2015;17(9):667–671. <https://doi.org/10.1089/dia.2015.0007>.
  31. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. *Lancet Diabetes Endocrinol.* 2021;9(7):419–426. [https://doi.org/10.1016/s2213-8587\(21\)00088-7](https://doi.org/10.1016/s2213-8587(21)00088-7).
  32. Iliodromiti S, McLaren J, Ghouri N, et al. Liver, visceral and subcutaneous fat in men and women of South Asian and white European descent: a systematic review and meta-analysis of new and published data. *Diabetologia.* 2023;66(1):44–56. <https://doi.org/10.1007/s00125-022-05803-5>.
  33. NICE Evidence Reviews Collection. *Evidence Review for Accuracy of Anthropometric Measures in Assessing Health Risks Associated with Overweight and Obesity in Adults: Weight Management Suite.* National Institute for Health and Care Excellence (NICE); 2022.
  34. ElSayed NA, Aleppo G, Aroda VR, et al. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2023. *Diabetes Care.* 2023;46(Suppl 1):S128–S139. <https://doi.org/10.2337/dc23-S008>.
  35. Haam JH, Kim BT, Kim EM, et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. *J Obes Metab Syndr.* 2023;32(2):121–129. <https://doi.org/10.7570/jomes23031>.
  36. Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. *Circ J.* 2002;66(11):987–992. <https://doi.org/10.1253/circj.66.987>.
  37. Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. *Biomed Environ Sci.* 2002;15(1):83–96.
  38. Esparza-Hurtado N, Martagon AJ, Hart-Vazquez DP, Rodríguez-Tadeo A, González-Arellanes R. Novel BMI cutoff points for obesity diagnosis in older Hispanic adults. *Sci Rep.* 2024;14(1):27498. <https://doi.org/10.1038/s41598-024-65553-9>.
  39. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. *Obes Pillars.* 2022;1:100004. <https://doi.org/10.1016/j.obpill.2021.100004>.
  40. Donini LM, Busetto L, Bauer JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. *Clin Nutr.* 2020;39(8):2368–2388. <https://doi.org/10.1016/j.clnu.2019.11.024>.
  41. Ross R, Neeland JJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. *Nat Rev Endocrinol.* 2020;16(3):177–189. <https://doi.org/10.1038/s41574-019-0310-7>.
  42. Tham KW, Abdul Ghani R, Cua SC, et al. Obesity in South and Southeast Asia—a new consensus on care and management. *Obes Rev.* 2023;24(2):e13520. <https://doi.org/10.1111/obr.13520>.
  43. Obesity: identification, assessment and management. <https://www.nice.org.uk/guidance/CG189>; Updated July 26, 2023. Accessed December 16, 2024.
  44. Heo M, Faith MS, Pietrobelli A, Heymsfield SB. Percentage of body fat cutoffs by sex, age, and race-ethnicity in the US adult population from NHANES 1999–2004. *Am J Clin Nutr.* 2012;95(3):594–602. <https://doi.org/10.3945/ajcn.111.025171>.
  45. Potter AW, Chin GC, Looney DP, Friedl KE. Defining overweight and obesity by percent body fat instead of body mass index. *J Clin Endocrinol Metabol.* 2025;110(4):e1103–e1107. <https://doi.org/10.1210/clinem.dgae341>.
  46. Macek P, Biskup M, Terek-Derszniak M, et al. Optimal body fat percentage cut-off values in predicting the obesity-related cardiovascular risk factors: a cross-sectional cohort study. *Diabetes Metab Syndr Obes.* 2020;13:1587–1597. <https://doi.org/10.2147/dms0.S248444>.
  47. Liu C, Cheng KY, Tong X, et al. The role of obesity in sarcopenia and the optimal body composition to prevent against sarcopenia and obesity. *Front Endocrinol (Lausanne).* 2023;14:1077255. <https://doi.org/10.3389/fendo.2023.1077255>.
  48. Tinsley GM, Heymsfield SB. Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. *J Endocr Soc.* 2024;8(11):bvae164. <https://doi.org/10.1210/jendso/bvae164>.
  49. Marra M, Sammarco R, De Lorenzo A, et al. Assessment of body composition in health and disease using bioelectrical impedance analysis (BIA) and dual energy x-ray absorptiometry (DXA): a critical overview. *Contrast Media Mol Imaging.* 2019;2019:3548284. <https://doi.org/10.1155/2019/3548284>.
  50. Campa F, Toselli S, Mazzilli M, Gobbo LA, Coratella G. Assessment of body composition in athletes: a narrative review of available methods with special reference to quantitative and qualitative bioimpedance analysis. *Nutrients.* 2021;13(5):1620. <https://doi.org/10.3390/nu13051620>.
  51. Bosy-Westphal A, Müller MJ. Diagnosis of obesity based on body composition-associated health risks—time for a change in paradigm. *Obes Rev.* 2021;22(Suppl 2):e13190. <https://doi.org/10.1111/obr.13190>.
  52. Santos DA, Dawson JA, Matias CN, et al. Reference values for body composition and anthropometric measurements in athletes. *PloS One.* 2014;9(5):e97846. <https://doi.org/10.1371/journal.pone.0097846>.
  53. Bonilla DA, De León LG, Alexander-Cortez P, et al. Simple anthropometry-based calculations to monitor body composition in athletes: scoping review and reference values. *Nutr Health.* 2022;28(1):95–109. <https://doi.org/10.1177/02601060211002941>.
  54. Ceniccola GD, Castro MG, Piovacari SMF, et al. Current technologies in body composition assessment: advantages and disadvantages. *Nutrition.* 2019;62:25–31. <https://doi.org/10.1016/j.nut.2018.11.028>.
  55. Ward LC. Bioelectrical impedance analysis for body composition assessment: reflections on accuracy, clinical utility, and standardisation. *Eur J Clin Nutr.* 2019;73(2):194–199. <https://doi.org/10.1038/s41430-018-0335-3>.
  56. Opio J, Croker E, Odongo GS, Attia J, Wynne K, McEvoy M. Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: a systematic review and meta-analysis of prospective cohort studies. *Obes Rev.* 2020;21(12):e13127. <https://doi.org/10.1111/obr.13127>.
  57. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet.* 2008;371(9612):569–578. [https://doi.org/10.1016/s0140-6736\(08\)60269-x](https://doi.org/10.1016/s0140-6736(08)60269-x).
  58. Sharma AM, Campbell-Scherer DL. Redefining obesity: beyond the numbers. *Obesity (Silver Spring).* 2017;25(4):660–661. <https://doi.org/10.1002/oby.21801>.
  59. Guo F, Garvey WT. Cardiometabolic disease staging predicts effectiveness of weight-loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine/topiramate extended release. *Diabetes Care.* 2017;40(7):856–862. <https://doi.org/10.2337/dc17-0088>.
  60. Atlantis E, Sahebolamri M, Cheema BS, Williams K. Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: a rapid review of observational studies. *Obes Rev.* 2020;21(11):e13120. <https://doi.org/10.1111/obr.13120>.
  61. Pajecski D, Dantas ACB, Santo MA, Tess BH. Beyond the BMI: a critical analysis of the Edmonton Obesity Staging System and the new guidelines for indications for metabolic and bariatric surgery. *Obes Surg.* 2023;33(4):1276–1278. <https://doi.org/10.1007/s11695-023-06516-3>.
  62. Wilkinson L, Yi N, Mehta T, Judd S, Garvey WT. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: a nationwide cohort and modeling study. *PLoS Med.* 2020;17(8):e1003232. <https://doi.org/10.1371/journal.pmed.1003232>.
  63. Howell CR, Zhang L, Mehta T, et al. Cardiometabolic disease staging and major adverse cardiovascular event prediction in 2 prospective cohorts. *JACC Adv.* 2024;3(4):100868. <https://doi.org/10.1016/j.jaccadv.2024.100868>.
  64. Kurnool S, McCowen KC, Bernstein NA, Malhotra A. Sleep apnea, obesity, and diabetes - an intertwined trio. *Curr Diab Rep.* 2023;23(7):165–171. <https://doi.org/10.1007/s11892-023-01510-6>.
  65. Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. *Arthritis Rheumatol.* 2016;68(8):1869–1875. <https://doi.org/10.1002/art.39707>.
  66. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract.* 2022;28(5):528–562. <https://doi.org/10.1016/j.eprac.2022.03.010>.
  67. European Association for the Study of the Liver, European Association for the Study of Diabetes. European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol.* 2024;81(3):492–542. <https://doi.org/10.1016/j.jhep.2024.04.031>.
  68. European Association for the Study of the Liver, European Association for the Study of Diabetes. European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *Obes Facts.* 2024;17(4):374–444. <https://doi.org/10.1159/000539371>.
  69. European Association for the Study of the Liver, European Association for the Study of Diabetes. European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. *Diabetologia.* 2024;67(11):2375–2392. <https://doi.org/10.1007/s00125-024-06196-3>.
  70. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. *Diabetes Care.* 2025;48(1 Suppl 1):S27–S49. <https://doi.org/10.2337/dc25-S002>.
  71. Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. *Obes Facts.* 2016;9(3):158–173. <https://doi.org/10.1159/000445061>.
  72. Mainieri F, La Bella S, Rinaldi M, Chiarelli F. Rare genetic forms of obesity in childhood and adolescence, a comprehensive review of their molecular mechanisms and diagnostic approach. *Eur J Pediatr.* 2023;182(11):4781–4793. <https://doi.org/10.1007/s00431-023-05159-x>.

73. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100(2):342–362. <https://doi.org/10.1210/jc.2014-3415>.
74. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care*. 2019;42(5):731–754. <https://doi.org/10.2337/dci19-0014>.
75. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389(10077):1399–1409. [https://doi.org/10.1016/s0140-6736\(17\)30069-7](https://doi.org/10.1016/s0140-6736(17)30069-7).
76. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. *Diabetes Care*. 2014;37(4):912–921. <https://doi.org/10.2337/dc13-1518>.
77. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes care*. 2006;29(9):2102–2107. <https://doi.org/10.2337/dc06-056074>.
78. Booth H, Khan O, Prevost T, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. *Lancet Diabetes Endocrinol*. 2014;2(12):963–968. [https://doi.org/10.1016/s2213-8587\(14\)70214-176](https://doi.org/10.1016/s2213-8587(14)70214-176).
79. Draznin B, Aroda VR, Bakris G, et al. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022. *Diabetes care*. 2022;45(Suppl 1):S113–S124. <https://doi.org/10.2337/dc22-S00877>.
80. Galaviz KI, Weber MB, Straus A, Haw JS, Narayan KMV, Ali MK. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. *Diabetes Care*. 2018;41(7):1526–1534. <https://doi.org/10.2337/dc17-22278>.
81. Blonde L, Umperiez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. *Endocr Pract*. 2022;28(10):923–1049. <https://doi.org/10.1016/j.eprac.2022.08.002>.
82. Kanbour S, Ageeb RA, Malik RA, Abu-Raddad LJ. Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials. *Lancet Diabetes Endocrinol*. 2025;13(4):294–306. [https://doi.org/10.1016/s2213-8587\(24\)00346-279](https://doi.org/10.1016/s2213-8587(24)00346-279).
83. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet (London, England)*. 2018;391(10120):541–551. [https://doi.org/10.1016/s0140-6736\(17\)33102-180](https://doi.org/10.1016/s0140-6736(17)33102-180).
84. Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. *Diabetologia*. 2016;59(5):945–953. <https://doi.org/10.1007/s00125-016-3903-x81>.
85. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45(11):2753–2786. <https://doi.org/10.2337/dci22-0034>.
86. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes care*. 2011;34(7):1481–1486. <https://doi.org/10.2337/dc10-241584>.
87. Shantha GP, Kumar AA, Kahan S, Cheskin LJ. Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study. *Diabetes Educ*. 2012;38(3):417–426. <https://doi.org/10.1177/014572171244329385>.
88. Gregg EW, Jakicic JM, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol*. 2016;4(11):913–921. [https://doi.org/10.1016/s2213-8587\(16\)30162-086](https://doi.org/10.1016/s2213-8587(16)30162-086).
89. Thom G, Messow CM, Leslie WS, et al. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabetic Med*. 2021;38(8):e14395. <https://doi.org/10.1111/dme.1439588>.
90. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. *Diabetes Care*. 2025;48(Supplement 1):S167–S180. <https://doi.org/10.2337/dc25-S00889>.
91. Singh P, Adderley NJ, Hazlehurst J, et al. Prognostic models for predicting remission of diabetes following bariatric surgery: a systematic review and meta-analysis. *Diabetes Care*. 2021;44(11):2626–2641. <https://doi.org/10.2337/dc21-0166>.
92. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol*. 2019;7(5):344–355. [https://doi.org/10.1016/s2213-8587\(19\)30068-387](https://doi.org/10.1016/s2213-8587(19)30068-387).
93. Hall ME, Cohen JB, Ard JD, et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. *Hypertension*. 2021;78(5):e38–e50. <https://doi.org/10.1161/hyp.000000000000202>.
94. Fantin F, Giani A, Zoico E, Rossi AP, Mazzali G, Zamboni M. Weight loss and hypertension in obese subjects. *Nutrients*. 2019;11(7). <https://doi.org/10.3390/nu11071667>.
95. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111–188. <https://doi.org/10.1093/eurheartj/ehz45593>.
96. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary. *Endocr Pract*. 2020;26(10):1196–1224. <https://doi.org/10.4158/cs-2020-0490>.
97. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023;77(5):1797–1835. <https://doi.org/10.1097/hep.00000000000032396>.
98. Koh B, Xiao J, Ng CH, et al. Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: systematic review and network meta-analysis. *Hepatology*. 2024. <https://doi.org/10.1097/hep.000000000000102897>.
99. Sabench F, Rusu EC, Clavero-Mestres H, et al. Metabolic-associated fatty liver disease and weight loss after bariatric surgery: a systematic review and meta-analysis. *Obes Surg*. 2024;34(12):4459–4471. <https://doi.org/10.1007/s11695-024-07585-8>.
100. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N Engl J Med*. 2021;384(12):1113–1124. <https://doi.org/10.1056/NEJMoa2028395>.
101. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. *Aliment Pharmacol Ther*. 2024;60(11-12):1525–1533. <https://doi.org/10.1111/apt.18331>.
102. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. *N Engl J Med*. 2024;391(4):299–310. <https://doi.org/10.1056/NEJMoa2401943>.
103. Younossi ZM, Corey KE, Lim JK AGA. Clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. *Gastroenterology*. 2021;160(3):912–918. <https://doi.org/10.1053/j.gastro.2020.11.05199>.
104. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2021;161(5):1657–1669. <https://doi.org/10.1053/j.gastro.2021.07.049100>.
105. Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. *BMC Endocr Disord*. 2022;22(1):63. <https://doi.org/10.1186/s12902-022-00980-1>.
106. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. *Sleep*. 2012;35(11):1529–1539. <https://doi.org/10.5665/sleep.2204>.
107. Malhotra A, Heilmann CR, Banerjee KK, Dunn JP, Bunck MC, Bednarik J. Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis. *Sleep Med*. 2024;121:26–31. <https://doi.org/10.1016/j.sleep.2024.06.014104>.
108. Georgoulis M, Yiannakouris N, Kechribari I, et al. Dose-response relationship between weight loss and improvements in obstructive sleep apnea severity after a diet/lifestyle interventions: secondary analyses of the “MIMOSA” randomized clinical trial. *J Clin Sleep Med*. 2022;18(5):1251–1261. <https://doi.org/10.5664/jcsm.9834>.
109. Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. *Sleep*. 2013;36(5):641–649a. <https://doi.org/10.5665/sleep.2618>.
110. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. *N Engl J Med*. 2009;360(5):481–490. <https://doi.org/10.1056/NEJMoa0806375108>.
111. Vissers D, Neels H, Vermandel A, et al. The effect of non-surgical weight loss interventions on urinary incontinence in overweight women: a systematic review and meta-analysis. *Obes Rev*. 2014;15(7):610–617. <https://doi.org/10.1111/obr.12170109>.
112. Wu JM. Stress incontinence in women. *N Engl J Med*. 2021;384(25):2428–2436. <https://doi.org/10.1056/NEJMcp1914037110>.
113. Purwar B, Cartwright R, Cavalcanti G, Digesu GA, Fernando R, Khullar V. The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis. *Int Urogynecol J*. 2019;30(8):1225–1237. <https://doi.org/10.1007/s00192-018-03865-x>.
114. Mehta RS, Staller K, Chan AT. Review of gastroesophageal reflux disease. *JAMA*. 2021;325(14):1472. <https://doi.org/10.1001/jama.2021.1438112>.
115. De Bortoli N, Tolone S, Savarino EV. Weight loss is truly effective in reducing symptoms and proton pump inhibitor use in patients with gastroesophageal reflux disease. *Clin Gastroenterol Hepatol*. 2015;13(11):2023. <https://doi.org/10.1016/j.cgh.2015.05.034113>.
116. Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. *Clin Gastroenterol Hepatol*. 2016;14(2):175–182.e1-3. <https://doi.org/10.1016/j.cgh.2015.04.176>.
117. Skubleny D, Switzer NJ, Gill RS, et al. The impact of bariatric surgery on polycystic ovary syndrome: A systematic review and meta-analysis. *Obes Surg*. 2016;26(1):169–176. <https://doi.org/10.1007/s11695-015-1902>.



118. Yue W, Huang X, Zhang W, et al. Metabolic surgery on patients with polycystic ovary syndrome: A systematic review and meta-Analysis. *Front Endocrinol (Lausanne)*. 2022;13:848947. <https://doi.org/10.3389/fendo.2022.848947>.
119. Lie Fong S, Douma A, Verhaeghe J. Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and obese women with PCOS? *J Gynecol Obstet Hum Reprod*. 2021;50(6):101894. <https://doi.org/10.1016/j.jogoh.2020.101894>.
120. Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. *Lancet Diabetes Endocrinol*. 2022;10(9):668–680. [https://doi.org/10.1016/s2213-8587\(22\)00163-2](https://doi.org/10.1016/s2213-8587(22)00163-2).
121. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. *J Clin Endocrinol Metab*. 2021;106(3):e1071–e1083. <https://doi.org/10.1210/clinem/dgaa839>.
122. Hazlehurst JM, Singh P, Bhogal G, Broughton S, Tahrani AA. How to manage weight loss in women with obesity and PCOS seeking fertility? *Clin Endocrinol (Oxf)*. 2022;97(2):208–216. <https://doi.org/10.1111/cen.14726>.
123. Yeh HC, Bantle JP, Cassidy-Begay M, et al. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD Randomized Clinical Trial. *Obesity (Silver SpringMd)*. 2020;28(9):1678–1686. <https://doi.org/10.1002/oby.22936>.
124. Zhang X, Rhoades J, Caan BJ, et al. Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. *Int J Gynecol Cancerr*. 2019;29(9):1361–1371. <https://doi.org/10.1136/ijgc-2019-000728>.
125. Chlebowski RT, Luo J, Anderson GL, et al. Weight loss and breast cancer incidence in postmenopausal women. *Cancer*. 2019;125(2):205–212. <https://doi.org/10.1002/cncr.31687>.
126. Feigelson HS, Caan B, Weinmann S, et al. Bariatric surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women. *Ann Surg*. 2020;272(6):1053–1059. <https://doi.org/10.1097/sla.0000000000003331>.
127. Teras LR, Patel AV, Wang M, et al. Sustained weight loss and risk of breast cancer in women 50 years and older: A pooled analysis of prospective data. *J Natl Cancer Inst*. 2020;112(9):929–937. <https://doi.org/10.1093/jnci/djz226>.
128. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2021;143(21):e984–e1010. <https://doi.org/10.1161/cir.0000000000000973>.
129. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med*. 2023;389(24):2221–2232. <https://doi.org/10.1056/NEJMoa2307563>.
130. Katsoulis M, Stavola BD, Diaz-Ordaz K, et al. Weight change and the onset of cardiovascular diseases: Emulating trials using electronic health records. *Epidemiology*. 2021;32(5):744–755. <https://doi.org/10.1097/ede.0000000000001393>.
131. Haywood CJ, Prendergast LA, Lim R, Lappas M, Lim WK, Proietto J. Obesity in older adults: effect of degree of weight loss on cardiovascular markers and medications. *Clin Obes*. 2019;9(4):e12316. <https://doi.org/10.1111/cob.12316>.
132. Kane J, Mehmood T, Munir I, et al. Cardiovascular risk reduction associated with pharmacological weight loss: a meta-analysis. *Int J Clin Res trials*. 2019;4. <https://doi.org/10.15344/2456-8007/2019/131>.
133. Capristo E, Maione A, Lucisano G, Russo MF, Mingrone G, Nicolucci A. Effects of weight loss medications on mortality and cardiovascular events: a systematic review of randomized controlled trials in adults with overweight and obesity. *Nutr Metab Cardiovasc Dis*. 2021;31(9):2587–2595. <https://doi.org/10.1016/j.numecd.2021.05.023>.
134. Sutanto A, Wungu CDK, Susilo H, Sutanto H. Reduction of major adverse cardiovascular events (MACE) after bariatric surgery in patients with obesity and cardiovascular diseases: A systematic review and meta-analysis. *Nutrients*. 2021;13(10). <https://doi.org/10.3390/nu13103568>.
135. Tang B, Zhang Y, Wang Y, Wang X, An Z, Yu X. Effect of bariatric surgery on long-term cardiovascular outcomes: a systematic review and meta-analysis of population-based cohort studies. *Surg Obes Relat Dis*. 2022;18(8):1074–1086. <https://doi.org/10.1016/j.soard.2022.05.007>.
136. Aminian A, Wilson R, Zajichek A, et al. Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care. *Diabetes Care*. 2021;44(11):2552–2563. <https://doi.org/10.2337/dc20-3023>.
137. Koskinas KC, Van Craenenbroeck EM, Antoniadis C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. *Eur J Prev Cardiol*. 2025;32(3):184–220. <https://doi.org/10.1093/eurjpc/zwae279>.
138. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. *Int J Cardiol*. 2014;173(1):20–28. <https://doi.org/10.1016/j.ijcard.2014.02.026>.
139. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. *Curr Obes Rep*. 2017;6(2):187–194. <https://doi.org/10.1007/s13679-017-0262-y>.
140. Tahrani AA, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: a review. *Obesity (Silver Spring)*. 2022;30(4):802–840. <https://doi.org/10.1002/oby.23371>.
141. Nackers LM, Ross KM, Perri MG. The association between rate of initial weight loss and long-term success in obesity treatment: does slow and steady win the race? *Int J Behav Med*. 2010;17(3):161–167. <https://doi.org/10.1007/s12529-010-9092-y>.
142. Varkevisser RDM, van Stralen MM, Kroeze W, Ket JCF, Steenhuis IHM. Determinants of weight loss maintenance: a systematic review. *Obes Rev*. 2019;20(2):171–211. <https://doi.org/10.1111/obr.12772>.
143. Chopra S, Malhotra A, Ranjan P, et al. Predictors of successful weight loss outcomes amongst individuals with obesity undergoing lifestyle interventions: a systematic review. *Obes Rev*. 2021;22(3):e13148. <https://doi.org/10.1111/obr.13148>.
144. Salminen P, Kow L, Aminian A, et al. IFSO Consensus on definitions and clinical practice guidelines for obesity management—an International Delphi Study. *Obes Surg*. 2024;34(1):30–42. <https://doi.org/10.1007/s11695-023-06913-8>.
145. Vink RG, Roumans NJ, Arkenbosch LA, Mariman EC, van Baak MA. The effect of rate of weight loss on long-term weight regain in adults with overweight and obesity. *Obesity (Silver Spring)*. 2016;24(2):321–327. <https://doi.org/10.1002/oby.21346>.
146. Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. *Diabetes Obes Metab*. 2021;23(Suppl 1):50–62. <https://doi.org/10.1111/dom.14200>.
147. Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: a review of current evidence. *Curr Obes Rep*. 2023;12(3):207–222. <https://doi.org/10.1007/s13679-023-00518-z>.
148. Cohen JB. Hypertension in obesity and the impact of weight loss. *Curr Cardiol Rep*. 2017;19(10):98. <https://doi.org/10.1007/s11886-017-0912-4>.
149. Kumar AA, Palamaner Subash Shanthia G, Kahan S, Samson RJ, Boddu ND, Cheskin LJ. Intentional weight loss and dose reductions of anti-diabetic medications—a retrospective cohort study. *PLoS One*. 2012;7(2):e32395. <https://doi.org/10.1371/journal.pone.0032395>.
150. Malik A, Malik MI, Javaid S, Qureshi S, Nadir A. Comparative effectiveness of metabolic and bariatric surgeries: a network meta-analysis. *Int J Obes (Lond)*. 2025;49(1):54–62. <https://doi.org/10.1038/s41366-024-01648-7>.
151. Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Diabetes Care*. 2016;39(6):861–877. <https://doi.org/10.2337/dc16-0236>.
152. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. *Obes Surg*. 2023;33(1):3–14. <https://doi.org/10.1007/s11695-022-06332-1>.
153. De Luca M, Shikora S, Eisenberg D, et al. Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO/ASMBS). *Surg Obes Relat Dis*. 2024;20(11):991–1025. <https://doi.org/10.1016/j.soard.2024.05.009>.
154. Cohen RV, Busetto L, Levinson R, Le Roux CW, Salminen P, Prager G. International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). *Br J Surg*. 2024;111(12):znaz283. <https://doi.org/10.1093/bjs/znaz283>.
155. Mechanick JL, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. *Obesity (Silver Spring)*. 2020;28(4):O1–O58. <https://doi.org/10.1002/oby.22719>.
156. Rajala MW, Scherer PE. Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology*. 2003;144(9):3765–3773. <https://doi.org/10.1210/en.2003-0580>.
157. Vainshtein A, Sandri M. Signaling pathways that control muscle mass. *Int J Mol Sci*. 2020;21(13):4759. <https://doi.org/10.3390/ijms21134759>.
158. Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. *J Am Diet Assoc*. 2002;102(11):1621–1630. [https://doi.org/10.1016/s0002-8223\(02\)90346-9](https://doi.org/10.1016/s0002-8223(02)90346-9).
159. Frankenfield D, Roth-Yousey L, Compher C. Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review. *J Am Diet Assoc*. 2005;105(5):775–789. <https://doi.org/10.1016/j.jada.2005.02.005>.
160. Ashtary-Larky D, Bagheri R, Abbasnezhad A, Tinsley GM, Alipour M, Wong A. Effects of gradual weight loss v. rapid weight loss on body composition and RMR: a systematic review and meta-analysis. *Br J Nutr*. 2020;124(11):1121–1132. <https://doi.org/10.1017/s000711452000224x>.
161. Martins C, Gower BA, Hunter GR. Metabolic adaptation delays time to reach weight loss goals. *Obesity (Silver Spring)*. 2022;30(2):400–406. <https://doi.org/10.1002/oby.23333>.
162. Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. *Gastroenterology*. 2017;152(7):1718–1727.e3. <https://doi.org/10.1053/j.gastro.2017.01.052>.
163. Santarpia L, Contaldo F, Pisanisi F. Body composition changes after weight-loss interventions for overweight and obesity. *Clin Nutr*. 2013;32(2):157–161. <https://doi.org/10.1016/j.clnu.2012.08.016>.



164. Hassapidou M, Vlassopoulos A, Kalliostra M, et al. European Association for the Study of Obesity position statement on medical nutrition therapy for the management of overweight and obesity in adults developed in collaboration with the European Federation of the Associations of Dietitians. *Obes Facts*. 2023;16(1):11–28. <https://doi.org/10.1159/000528083>.
165. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014;129(25 Suppl 2):S102–S138. <https://doi.org/10.1161/01.cir.0000437739.71477.ee>.
166. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*. 2022;387(3):205–216. <https://doi.org/10.1056/NEJMoa2206038>.
167. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384(11):989–1002. <https://doi.org/10.1056/nejmoa2032183>.
168. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011;377(9774):1341–1352. [https://doi.org/10.1016/S0140-6736\(11\)60205-5](https://doi.org/10.1016/S0140-6736(11)60205-5).
169. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2010;376(9741):595–605. [https://doi.org/10.1016/S0140-6736\(10\)60888-4](https://doi.org/10.1016/S0140-6736(10)60888-4).
170. Kushner RF, Batsis JA, Butsch WS, et al. Weight history in clinical practice: the state of the science and future directions. *Obesity (Silver Spring)*. 2020;28(1):9–17. <https://doi.org/10.1002/oby.22642>.
171. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. *Obesity (Silver Spring)*. 2016;24(8):1612–1619. <https://doi.org/10.1002/oby.21538>.
172. Carneiro IP, Elliott SA, Siervo M, et al. Is obesity associated with altered energy expenditure? *Adv Nutr*. 2016;7(3):476–487. <https://doi.org/10.3945/an.115.008755>.
173. Ricciardi R, Talbot LA. Use of bioelectrical impedance analysis in the evaluation, treatment, and prevention of overweight and obesity. *J Am Acad Nurse Pract*. 2007;19(5):235–241. <https://doi.org/10.1111/j.1745-7599.2007.00220.x>.
174. National Institute of Diabetes and Digestive and Kidney Diseases. Body weight planner. <https://www.niddk.nih.gov/bwp>. Accessed August 3, 2023.
175. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. *JAMA*. 2005;293(1):43–53. <https://doi.org/10.1001/jama.293.1.43>.
176. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation*. 1999;99(6):779–785. <https://doi.org/10.1161/01.cir.99.6.779>.
177. Estruch R, Ros E, Salas-Salvadó J, et al. Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med*. 2013;368:1279–1290. *N Engl J Med*. 2018;378(25):2441–1290. <https://doi.org/10.1056/NEJMc1806491>.
178. Delgado-Lista J, Alcalá-Díaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet*. 2022;399(10338):1876–1885. [https://doi.org/10.1016/S0140-6736\(22\)00122-2](https://doi.org/10.1016/S0140-6736(22)00122-2).
179. Salas-Salvadó J, Bulló M, Babio N, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care*. 2011;34(1):14–19. <https://doi.org/10.2337/dc10-1288>. Erratum in: *Diabetes Care*. 2018;41(10):2259–2260. <https://doi.org/10.2337/dc18-er10>.
180. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. *CMAJ*. 2020;192(31):E875–E891. <https://doi.org/10.1503/cmaj.191707>.
181. Noronha JC, Nishi SK, Braunstein CR, et al. The effect of liquid meal replacements on cardiometabolic risk factors in overweight/obese individuals with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Care*. 2019;42(5):767–776. <https://doi.org/10.2337/dc18-2270>.
182. Astbury NM, Piernas C, Hartmann-Boyce J, Lapworth S, Aveyard P, Jebb SA. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. *Obes Rev*. 2019;20(4):569–587. <https://doi.org/10.1111/obr.12816>.
183. Min J, Kim SY, Shin IS, Park YB, Lim YW. The effect of meal replacement on weight loss according to calorie-restriction type and proportion of energy intake: a systematic review and meta-analysis of randomized controlled trials. *J Acad Nutr Diet*. 2021;121(8):1551–1564.e3. <https://doi.org/10.1016/j.jand.2021.05.001>.
184. Hartmann-Boyce J, Ordóñez-Mena JM, Theodoulou A, et al. Impact of program characteristics on weight loss in adult behavioral weight management interventions: systematic review and component network meta-analysis. *Obesity (Silver Spring)*. 2022;30(9):1778–1786. <https://doi.org/10.1002/oby.23505>.
185. Churuangskuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. *Diabetologia*. 2022;65(1):14–36. <https://doi.org/10.1007/s00125-021-05577-2>.
186. Schroot MM, Joris PJ, Plat J, Mensink RP. Effects of intermittent energy restriction compared with those of continuous energy restriction on body composition and cardiometabolic risk markers – a systematic review and meta-analysis of randomized controlled trials in adults. *Adv Nutr*. 2024;15(1):100130. <https://doi.org/10.1016/j.advnut.2023.10.003>.
187. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. *J Clin Med*. 2022;12(1):145. <https://doi.org/10.3390/jcm12010145>.
188. Gill SK, Rossi M, Bajka B, Whelan K. Dietary fibre in gastrointestinal health and disease. *Nat Rev Gastroenterol Hepatol*. 2021;18(2):101–116. <https://doi.org/10.1038/s41575-020-00375-4>.
189. Belza A, Ritz C, Sørensen MQ, Holst JJ, Rehfeldt JF, Astrup A. Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety. *Am J Clin Nutr*. 2013;97(5):980–989. <https://doi.org/10.3945/ajcn.112.047563>.
190. Mikkelsen PB, Toubro S, Astrup A. Effect of fat-reduced diets on 24-h energy expenditure: comparisons between animal protein, vegetable protein, and carbohydrate. *Am J Clin Nutr*. 2000;72(5):1135–1141. <https://doi.org/10.1093/ajcn/72.5.1135>.
191. Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2012;96(6):1281–1298. <https://doi.org/10.3945/ajcn.112.044321>.
192. Oliveira CLP, Boulé NG, Sharma AM, et al. A high-protein total diet replacement increases energy expenditure and leads to negative fat balance in healthy, normal-weight adults. *Am J Clin Nutr*. 2021;113(2):476–487. <https://doi.org/10.1093/ajcn/nqaa283>.
193. Krieger JW, Sitren HS, Daniels MJ, Langkamp-Henken B. Effects of variation in protein and carbohydrate intake on body mass and composition during energy restriction: a meta-regression 1. *Am J Clin Nutr*. 2006;83(2):260–274. <https://doi.org/10.1093/ajcn/83.2.260>.
194. Bray GA, Ryan DH, Johnson W, et al. Markers of dietary protein intake are associated with successful weight loss in the POUNDS Lost trial. *Clin Obes*. 2017;7(3):166–175. <https://doi.org/10.1111/cob.12188>.
195. Jäger R, Kerkick CM, Campbell BI, et al. International Society of Sports Nutrition position stand: protein and exercise. *J Int Soc Sports Nutr*. 2017;14:20. <https://doi.org/10.1186/s12970-017-0177-8>.
196. Evangelista LS, Jose MM, Sallam H, et al. High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro-HEART trial. *ESC Heart Fail*. 2021;8(2):1342–1348. <https://doi.org/10.1002/ehf2.13213>.
197. Ikizler TA, Burrows JD, Byham-Gray LD, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 Update. *Am J Kidney Dis*. 2020;76(3 Suppl 1):S1–S107. <https://doi.org/10.1053/j.ajkd.2020.05.006>.
198. de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. *Kidney Int*. 2020;98(4):839–848. <https://doi.org/10.1016/j.kint.2020.06.024>.
199. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2022;102(5):974–989. <https://doi.org/10.1016/j.kint.2022.08.012>.
200. Phillips SM, Chevalier S, Leidy HJ. Correction: Protein “requirements” beyond the RDA: implications for optimizing health. *Appl Physiol Nutr Metab*. 2022;47(5):615. <https://doi.org/10.1139/apnm-2022-0131>.
201. Kokura Y, Ueshima J, Saino Y, Maeda K. Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: a systematic review and meta-analysis. *Clin Nutr ESPEN*. 2024;63:417–426. <https://doi.org/10.1016/j.clnesp.2024.06.030>.
202. Heymsfield SB, Shapses SA. Guidance on energy and macronutrients across the life span. *N Engl J Med*. 2024;390(14):1299–1310. <https://doi.org/10.1056/NEJMra2214275>.
203. Wu G. Dietary protein intake and human health. *Food Funct*. 2016;7(3):1251–1265. <https://doi.org/10.1039/c5fo01530h>.
204. Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK, American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. *Med Sci Sports Exerc*. 2009;41(2):459–471. <https://doi.org/10.1249/MSS.0b013e3181949333>.
205. Izquierdo M, Merchant RA, Morley JE, et al. International Exercise Recommendations in Older Adults (ICFSR): expert consensus guidelines. *J Nutr Health Aging*. 2021;25(7):824–853. <https://doi.org/10.1007/s12603-021-1665-8>.
206. Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. *Eur J Prev Cardiol*. 2022;29(17):2218–2237. <https://doi.org/10.1093/eurjpc/zwac187>.
207. Oppert JM, Bellicha A, van Baak MA, et al. Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. *Obes Rev*. 2021;22(Suppl 4):e13273. <https://doi.org/10.1111/obr.13273>.

208. Jakicic JM, Powell KE, Campbell WW, et al. Physical activity and the prevention of weight gain in adults: a systematic review. *Med Sci Sports Exerc.* 2019;51(6):1262–1269. <https://doi.org/10.1249/mss.0000000000001938>.
209. Zare R, Devrim-Lanpir A, Guazzotti S, et al. Effect of soy protein supplementation on muscle adaptations, metabolic and antioxidant status, hormonal response, and exercise performance of active individuals and athletes: a systematic review of randomised controlled trials. *Sports Med.* 2023;53(12):2417–2446. <https://doi.org/10.1007/s40279-023-01899-w>.
210. MacKenzie-Shalders K, Kelly JT, So D, Coffey VG, Byrne NM. The effect of exercise interventions on resting metabolic rate: a systematic review and meta-analysis. *J Sports Sci.* 2020;38(14):1635–1649. <https://doi.org/10.1080/02640414.2020.1754716>.
211. Christoffersen B, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E. Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. *Obesity (Silver Spring).* 2022;30(4):841–857. <https://doi.org/10.1002/oby.23374>.
212. Li R, Xia J, Zhang Xi, et al. Associations of muscle mass and strength with all-cause mortality among US older adults. *Med Sci Sports Exerc.* 2018;50(3):458–467. <https://doi.org/10.1249/mss.0000000000001448>.
213. Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis. *Nutrients.* 2018;10(4):423. <https://doi.org/10.3390/nu10040423>.
214. Lopez P, Taaffe DR, Galvão DA, et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: a systematic review and meta-analysis. *Obes Rev.* 2022;23(5):e13428. <https://doi.org/10.1111/obr.13428>.
215. Ashton RE, Tew GA, Anning JJ, Gilbert SE, Lewis L, Saxton JM. Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: systematic review with meta-analysis. *Br J Sports Med.* 2020;54(6):341–348. <https://doi.org/10.1136/bjsports-2017-098970>.
216. Orange ST, Madden LA, Vince RV. Resistance training leads to large improvements in strength and moderate improvements in physical function in adults who are overweight or obese: a systematic review. *J Physiother.* 2020;66(4):214–224. <https://doi.org/10.1016/j.jphys.2020.09.009>.
217. Nuijten MAH, Eijssvogels TMH, Monpellier VM, Janssen IMC, Hazebroek EJ, Hopman MTE. The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis. *Obes Rev.* 2022;23(1):e13370. <https://doi.org/10.1111/obr.13370>.
218. Roth C, Schoenfeld BJ, Behringer M. Lean mass sparing in resistance-trained athletes during caloric restriction: the role of resistance training volume. *Eur J Appl Physiol.* 2022;122(5):1129–1151. <https://doi.org/10.1007/s00421-022-04896-5>.
219. Morales-Marroquin E, Kohl 3rd HW, Knell G, de la Cruz-Muñoz N, Messiah SE. Resistance training in post-metabolic and bariatric surgery patients: a systematic review. *Obes Surg.* 2020;30(10):4071–4080. <https://doi.org/10.1007/s11695-020-04837-1>.
220. American College of Sports Medicine. Exercise is medicine. <https://www.exercisemedicine.org/>. Accessed August 28, 2023.
221. Zhu B, Shi C, Park CG, Zhao X, Reutrakul S. Effects of sleep restriction on metabolism-related parameters in healthy adults: a comprehensive review and meta-analysis of randomized controlled trials. *Sleep Med Rev.* 2019;45:18–30. <https://doi.org/10.1016/j.smrv.2019.02.002>.
222. Lin J, Jiang Y, Wang G, et al. Associations of short sleep duration with appetite-regulating hormones and adipokines: a systematic review and meta-analysis. *Obes Rev.* 2020;21(11):e13051. <https://doi.org/10.1111/obr.13051>.
223. Wu Y, Zhai L, Zhang D. Sleep duration and obesity among adults: a meta-analysis of prospective studies. *Sleep Med.* 2014;15(12):1456–1462. <https://doi.org/10.1016/j.sleep.2014.07.018>.
224. Fatima Y, Doi SA, Mamun AA. Sleep quality and obesity in young subjects: a meta-analysis. *Obes Rev.* 2016;17(11):1154–1166. <https://doi.org/10.1111/obr.12444>.
225. Bacaro V, Balleisio A, Cerolini S, et al. Sleep duration and obesity in adulthood: an updated systematic review and meta-analysis. *Obes Res Clin Pract.* 2020;14(4):301–309. <https://doi.org/10.1016/j.orcp.2020.03.004>.
226. Chaput J-P, McHill AW, Cox RC, et al. The role of insufficient sleep and circadian misalignment in obesity. *Nat Rev Endocrinol.* 2023;19(2):82–97. <https://doi.org/10.1038/s41574-022-00747-7>.
227. The Lancet Respiratory Medicine. Time to wake the giant of obstructive sleep apnoea. *Lancet Respir Med.* 2020;8(1):1. [https://doi.org/10.1016/S2213-2600\(19\)30449-7](https://doi.org/10.1016/S2213-2600(19)30449-7).
228. Patel SR, Mehra R. The weighty issue of obesity management in sleep apnea. *Chest.* 2015;148(5):1127–1129. <https://doi.org/10.1378/chest.15-1010>.
229. Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. *Diabetes Care.* 2009;32(6):1017–1019. <https://doi.org/10.2337/dc08-1776>.
230. Chen B, Drager LF, Peker Y, et al. Effect of continuous positive airway pressure on weight and local adiposity in adults with obstructive sleep apnea: a meta-analysis. *Ann Am Thorac Soc.* 2021;18(10):1717–1727. <https://doi.org/10.1513/AnnalsATS.202101-0600C>.
231. Drager LF, Brunoni AR, Jenner R, Lorenzi-Filho G, Benseñor IM, Lotufo PA. Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials. *Thorax.* 2015;70(3):258–264. <https://doi.org/10.1136/thoraxjnl-2014-205361>.
232. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med.* 2017;13(3):479–504. <https://doi.org/10.5664/jcs.m.6506>.
233. Ryan L, Coyne R, Heary C, et al. Weight stigma experienced by patients with obesity in healthcare settings: a qualitative evidence synthesis. *Obes Rev.* 2023;24(10):e13606. <https://doi.org/10.1111/obr.13606>.
234. Latner JD, Durso LE, Mond JM. Health and health-related quality of life among treatment-seeking overweight and obese adults: associations with internalized weight bias. *J Eat Disord.* 2013;1:3. <https://doi.org/10.1186/2050-2974-1-3>.
235. Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. *Obes Rev.* 2018;19(8):1141–1163. <https://doi.org/10.1111/obr.12701>.
236. Durso LE, Latner JD. Understanding self-directed stigma: development of the weight bias internalization scale. *Obesity (Silver Spring).* 2008;16(Suppl 2):S80–S86. <https://doi.org/10.1038/oby.2008.448>.
237. Lillis J, Luoma JB, Levin ME, Hayes SC. Measuring weight self-stigma: the weight self-stigma questionnaire. *Obesity (Silver Spring).* 2010;18(5):971–976. <https://doi.org/10.1038/oby.2009.353>.
238. Macho S, Andrés A, Saldaña C. Weight discrimination, BMI, or weight bias internalization? Testing the best predictor of psychological distress and body dissatisfaction. *Obesity (Silver Spring).* 2023;31(8):2178–2188. <https://doi.org/10.1002/oby.23802>.
239. Bąk-Sosnowska M, Moszak M, Doroszevska A, Wyleżół M, Ostrowska L, Bogdański P. Patient-centered care and “people-first language” as tools to prevent stigmatization of patients with obesity. *Pol Arch Intern Med.* 2022;132(10):16351. <https://doi.org/10.20452/pamw.16351>.
240. Dalle Grave R, Sartirana M, Calugi S. Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures. *Biopsychosoc Med.* 2020;14:5. <https://doi.org/10.1186/s13030-020-00177-9>.
241. Dawes AJ, Maggard-Gibbons M, Maher AR, et al. Mental health conditions among patients seeking and undergoing bariatric surgery: a meta-analysis. *JAMA.* 2016;315(2):150–163. <https://doi.org/10.1001/jama.2015.18118>.
242. Dandgey S, Patten E. Psychological considerations for the holistic management of obesity. *Clin Med (Lond).* 2023;23(4):318–322. <https://doi.org/10.7861/clinmed.2023-0146>.
243. Kahn SE, Deanfield JE, Jeppesen OK, et al. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial. *Diabetes Care.* 2024;47(8):1350–1359. <https://doi.org/10.2337/dc24-0491>.
244. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. *N Engl J Med.* 2025;392(10):958–971. <https://doi.org/10.1056/NEJMoa2410819>.
245. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care.* 2004;27(1):155–161. <https://doi.org/10.2337/diacare.27.1.155>.
246. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2023;402(10402):613–626. [https://doi.org/10.1016/s0140-6736\(23\)01200-x](https://doi.org/10.1016/s0140-6736(23)01200-x).
247. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet.* 2021;397(10278):971–984. [https://doi.org/10.1016/s0140-6736\(21\)00213-0](https://doi.org/10.1016/s0140-6736(21)00213-0).
248. Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trial. *Diabetes Care.* 2020;43(5):1085–1093. <https://doi.org/10.2337/dc19-1745>.
249. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. *Diabetes Care.* 1998;21(8):1288–1294. <https://doi.org/10.2337/diacare.21.8.1288>.
250. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. *Diabetes Care.* 2013;36(12):4022–4029. <https://doi.org/10.2337/dc13-0234>.
251. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. *Nat Med.* 2022;28(3):591–598. <https://doi.org/10.1038/s41591-022-01707-4>.
252. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2016;375(4):311–322. <https://doi.org/10.1056/NEJMoa1603827>.
253. Cohen JB, Gadde KM. Weight loss medications in the treatment of obesity and hypertension. *Curr Hypertens Rep.* 2019;21(2):16. <https://doi.org/10.1007/s11906-019-0915-1>.
254. Siebenhofer A, Winterholer S, Jeitler K, et al. Long-term effects of weight-reducing drugs in people with hypertension. *Cochrane Database Syst Rev.* 2021;1(1):CD007654. <https://doi.org/10.1002/14651858.CD007654.pub5>.



255. Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. *J Clin Med*. 2023;12(3):772. <https://doi.org/10.3390/jcm12030772>.
256. Kennedy C, Hayes P, Cicero AFG, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. *Eur Heart J*. 2024;45(38):4124–4134. <https://doi.org/10.1093/eurheartj/ehae564>.
257. Kanbay M, Copur S, Siritopol D, et al. Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials. *Diabetes Obes Metab*. 2023;25(12):3766–3778. <https://doi.org/10.1111/dom.15272>.
258. de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index  $\geq 27$  kg/m<sup>2</sup>: SURMOUNT-1 ambulatory blood pressure monitoring substudy. *Hypertension*. 2024;81(4):e41–e43. <https://doi.org/10.1161/hypertensionaha.123.22022>.
259. Krumholz HM, de Lemos JA, Sattar N, et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. *Heart*. 2024;110(19):1165–1171. <https://doi.org/10.1136/heartjnl-2024-324170>.
260. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUENCE): a randomized, placebo-controlled, phase 3 extension study. *Am J Clin Nutr*. 2012;95(2):297–308. <https://doi.org/10.3945/ajcn.111.024927>.
261. Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. *BMC Endocr Disord*. 2019;19(1):4. <https://doi.org/10.1186/s12902-018-0332-5>.
262. Sahebkar A, Simental-Mendía LE, Kovanen PT, Pedone C, Simental-Mendía M, Cicero AFG. Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials. *J Am Soc Hypertens*. 2018;12(2):80–96. <https://doi.org/10.1016/j.jash.2017.12.002>.
263. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med*. 2024;391(2):109–121. <https://doi.org/10.1056/NEJMoa2403347>.
264. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med*. 2017;377(9):839–848. <https://doi.org/10.1056/NEJMoa1616011>.
265. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. *Lancet Diabetes Endocrinol*. 2022;10(11):774–785. [https://doi.org/10.1016/s2213-8587\(22\)00243-1](https://doi.org/10.1016/s2213-8587(22)00243-1).
266. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med*. 2025;392(5):427–437. <https://doi.org/10.1056/NEJMoa2410027>.
267. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med*. 2023;389(12):1069–1084. <https://doi.org/10.1056/NEJMoa2306963>.
268. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *N Engl J Med*. 2024;391(17):1573–1583. <https://doi.org/10.1056/NEJMoa2403664>.
269. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. *N Engl J Med*. 2024;391(13):1193–1205. <https://doi.org/10.1056/NEJMoa2404881>.
270. Beccuti G, Bioletto F, Parasiliti-Caprino M, et al. Estimating cardiovascular benefits of tirzepatide in sleep apnea and obesity: insight from the SURMOUNT-OSA trials. *Curr Obes Rep*. 2024;13(4):739–742. <https://doi.org/10.1007/s13679-024-00592-x>.
271. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. *Int J Obes (Lond)*. 2016;40(8):1310–1319. <https://doi.org/10.1038/ijo.2016.52>.
272. Tirzepatide (Zepbound) for obstructive sleep apnea. *Med Lett Drugs Ther*. 2025;67(1722):29–31. <https://doi.org/10.58347/tml.2025.1722c>.
273. Harris SR, Carrillo M, Fujioka K. Binge-eating disorder and type 2 diabetes: a review. *Endocr Pract*. 2021;27(2):158–164. <https://doi.org/10.1016/j.epr.2020.10.005>.
274. Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA. Naltrexone/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial. *Obesity (Silver Spring)*. 2023;31(11):2762–2773. <https://doi.org/10.1002/oby.23898>.
275. Raffaelli B, García-Azorín D, Boucherie DM, et al. European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate. *J Headache Pain*. 2023;24(1):134. <https://doi.org/10.1186/s10194-023-01671-5>.
276. Murphy CE, Wang RC, Montoy JC, Whittaker E, Raven M. Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. *Addiction*. 2022;117(2):271–281. <https://doi.org/10.1111/add.15572>.
277. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. *Cochrane Database Syst Rev*. 2023;9(9):CD015226. <https://doi.org/10.1002/14651858.CD015226.pub2>.
278. Wharton S, Kamran E, Muqem M, Khan A, Christensen RAG. The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. *J Drug Assess*. 2019;8(1):184–191. <https://doi.org/10.1080/21556660.2019.1678478>.
279. Istfan NW, Lipartia M, Anderson WA, Hess DT, Apovian CM. Approach to the patient: management of the post-bariatric surgery patient with weight regain. *J Clin Endocrinol Metab*. 2020;106(1):251–263. <https://doi.org/10.1210/clinem/dgaa702>.
280. Burguera B, Griebeler ML, Garvey WT. Effective but inaccessible antiobesity medications: a call for sharing responsibility for improving access to evidence-based care. *Cleve Clin J Med*. 2024;91(11):671–676. <https://doi.org/10.3949/ccjm.91a.24068>.
281. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. *J Clin Pharmacol*. 1996;36(7):647–653. <https://doi.org/10.1002/j.1552-4604.1996.tb04230.x>.
282. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. *Pharmacotherapy*. 2002;22(7):814–822. <https://doi.org/10.1592/phco.22.11.814.33627>.
283. Buysschaert B, Aydin S, Morelle J, Hermans MP, Jadoul M, Demoulin N. Weight loss at a high cost: orlistat-induced late-onset severe kidney disease. *Diabetes Metab*. 2016;42(1):62–64. <https://doi.org/10.1016/j.diabet.2015.08.006>.
284. Xenical (orlistat) [package insert]. Nutley NJ. Roche Pharmaceuticals. 2009.
285. Istfan NW, Lipartia M, Anderson WA, Hess DT, Apovian CM. Approach to the patient: management of the post-bariatric surgery patient with weight regain. *J Clin Endocrinol Metab*. 2021;106(1):251–263. <https://doi.org/10.1210/clinem/dgaa702>.
286. Grunwald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. *Gastroenterology*. 2022;163(5):1198–1225. <https://doi.org/10.1053/j.gastro.2022.08.045>.
287. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2015;100(2):363–370. <https://doi.org/10.1210/jc.2014-3421>.
288. Xia Y, Kelton CM, Guo JJ, Bian B, Heaton PC. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. *Obesity (Silver Spring)*. 2015;23(8):1721–1728. <https://doi.org/10.1002/oby.21136>.
289. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. *Ann Intern Med*. 2005;143(5):380–385. <https://doi.org/10.7326/0003-4819-143-5-200509060-00013>.
290. Munro JF, Macculish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. *Br Med J*. 1968;1(5588):352–354. <https://doi.org/10.1136/bmj.1.5588.352>.
291. Long-term effectiveness of the antiobesity medication phentermine (LEAP). ClinicalTrials.gov identifier: NCT05176626. <https://clinicaltrials.gov/study/NCT05176626>; Updated October 18, 2024. Accessed December 13, 2024.
292. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. *Obesity (Silver Spring)*. 2019;27(4):591–602. <https://doi.org/10.1002/oby.22430>.
293. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. *Diabetes Obes Metab*. 2010;12(10):876–882. <https://doi.org/10.1111/j.1463-1326.2010.01242.x>.
294. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. *Obesity (Silver Spring)*. 2011;19(12):2351–2360. <https://doi.org/10.1038/oby.2011.94>.
295. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. *Obesity (Silver Spring)*. 2013;21(11):2163–2171. <https://doi.org/10.1002/oby.20584>.
296. Griebeler ML, Butsch WS, Rodriguez P, et al. The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters. *Obesity (Silver Spring)*. 2022;30(11):2194–2203. <https://doi.org/10.1002/oby.23548>.
297. Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine/topiramate for the treatment of adolescent obesity. *NEJM Evid*. 2022;1(6). 10.1056/evdoa2200014. <https://doi.org/10.1056/evdoa2200014>.
298. Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. *Expert Opin Drug Saf*. 2017;16(1):27–39. <https://doi.org/10.1080/14740338.2017.1247807>.
299. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). *Obesity (Silver Spring)*. 2012;20(2):330–342. <https://doi.org/10.1038/oby.2011.330>.
300. Ritchey ME, Harding A, Hunter S, et al. Cardiovascular safety during and after use of phentermine and topiramate. *J Clin Endocrinol Metab*. 2019;104(2):513–522. <https://doi.org/10.1210/jc.2018-01010>.
301. Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, for oral use [package insert]. Brentwood, TN: Curax; 2025.
302. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. *Pharmacol Res*. 2014;84:1–11. <https://doi.org/10.1016/j.phrs.2014.04.004>.

303. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity (Silver Spring)*. 2013;21(5):935–943. <https://doi.org/10.1002/oby.20309>.
304. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. *Obesity (Silver Spring)*. 2011;19(1):110–120. <https://doi.org/10.1038/oby.2010.147>.
305. Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. *Int J Obes (Lond)*. 2016;40(9):1369–1375. <https://doi.org/10.1038/ijo.2016.67>.
306. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. *JAMA*. 2016;315(10):990–1004. <https://doi.org/10.1001/jama.2016.1558>.
307. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. *Mol Metab*. 2021;46:101090. <https://doi.org/10.1016/j.molmet.2020.101090>.
308. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. *JCI Insight*. 2020;5(6):e133429. <https://doi.org/10.1172/jci.insight.133429>.
309. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. *Mol Metab*. 2022;57:101351. <https://doi.org/10.1016/j.molmet.2021.101351>.
310. *Saxenda (liraglutide) [package insert]*. Princeton, NJ: Novo Nordisk; 2020.
311. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*. 2015;373(1):11–22. <https://doi.org/10.1056/NEJMoa1411892>.
312. Fujioka K, O'Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. *Obesity (Silver Spring, Md)*. Nov 2016;24(11):2278–2288. <https://doi.org/10.1002/oby.21629>.
313. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. *N Engl J Med*. 2022;387(24):2245–2257. <https://doi.org/10.1056/NEJMoa2208601>.
314. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *Lancet Diabetes Endocrinol*. 2017;5(4):251–260. [https://doi.org/10.1016/s2213-8587\(17\)30013-x](https://doi.org/10.1016/s2213-8587(17)30013-x).
315. Åhrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes Endocrinol*. 2017;5(5):341–354. [https://doi.org/10.1016/s2213-8587\(17\)30092-x](https://doi.org/10.1016/s2213-8587(17)30092-x).
316. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. *Diabetes Care*. 2018;41(2):258–266. <https://doi.org/10.2337/dc17-0417>.
317. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. *Lancet Diabetes Endocrinol*. 2017;5(5):355–366. [https://doi.org/10.1016/s2213-8587\(17\)30085-2](https://doi.org/10.1016/s2213-8587(17)30085-2).
318. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. *J Clin Endocrinol Metab*. 2018;103(6):2291–2301. <https://doi.org/10.1210/je.2018-00070>.
319. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. *Diabetes Care*. 2019;42(9):1724–1732. <https://doi.org/10.2337/dc19-0749>.
320. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. *Diabetes Care*. 2019;42(12):2272–2281. <https://doi.org/10.2337/dc19-0883>.
321. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. *JAMA*. 2019;321(15):1466–1480. <https://doi.org/10.1001/jama.2019.2942>.
322. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet*. 2019;394(10192):39–50. [https://doi.org/10.1016/s0140-6736\(19\)31271-1](https://doi.org/10.1016/s0140-6736(19)31271-1).
323. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. *Lancet Diabetes Endocrinol*. 2019;7(7):515–527. [https://doi.org/10.1016/s2213-8587\(19\)30192-5](https://doi.org/10.1016/s2213-8587(19)30192-5).
324. Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. *Lancet Diabetes Endocrinol*. 2019;7(7):528–539. [https://doi.org/10.1016/s2213-8587\(19\)30194-9](https://doi.org/10.1016/s2213-8587(19)30194-9).
325. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. *Diabetes Care*. 2019;42(12):2262–2271. <https://doi.org/10.2337/dc19-0898>.
326. Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. *Lancet Diabetes Endocrinol*. 2020;8(5):377–391. [https://doi.org/10.1016/s2213-8587\(20\)30075-9](https://doi.org/10.1016/s2213-8587(20)30075-9).
327. Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. *Lancet Diabetes Endocrinol*. 2020;8(5):392–406. [https://doi.org/10.1016/s2213-8587\(20\)30074-7](https://doi.org/10.1016/s2213-8587(20)30074-7).
328. U.S. Food and Drug Administration. *Wegovy (semaglutide) injection, for subcutaneous use*. prescribing information; Updated November 2024. Accessed December 18, 2024. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/215256s021lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s021lbl.pdf). Accessed December 18, 2024.
329. U.S. Food and Drug Administration. *Rybelsus (semaglutide) tablets, oral use*. prescribing information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/213051s018lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf); Updated January 2024. Accessed December 18, 2024.
330. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med*. 2022;28(10):2083–2091. <https://doi.org/10.1038/s41591-022-02026-4>.
331. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2023;402(10403):705–719. [https://doi.org/10.1016/s0140-6736\(23\)01185-6](https://doi.org/10.1016/s0140-6736(23)01185-6).
332. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2019;381(9):841–851. <https://doi.org/10.1056/NEJMoa1901118>.
333. Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol*. 2021;9(9):563–574. [https://doi.org/10.1016/s2213-8587\(21\)00174-1](https://doi.org/10.1016/s2213-8587(21)00174-1).
334. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834–1844. <https://doi.org/10.1056/NEJMoa1607141>.
335. Perreault L, Davies M, Frías JP, et al. Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program. *Diabetes Care*. 2022;45(10):2396–2405. <https://doi.org/10.2337/dc21-1785>.
336. U.S. Food and Drug Administration. *Mounjaro (tirzepatide) injection, for subcutaneous use*. prescribing information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/215866s010s015s022lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s010s015s022lbl.pdf). Accessed February 11, 2025.
337. U.S. Food and Drug Administration. *Zepbound (tirzepatide) injection, for subcutaneous use*. prescribing information. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/217806Orig1s020lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf). Accessed February 11, 2025.
338. Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. *Int J Obes (Lond)*. 2023;47(8):677–685. <https://doi.org/10.1038/s41366-023-01321-5>.
339. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*. 2024;331(1):38–48. <https://doi.org/10.1001/jama.2023.24945>.
340. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med*. 2021;385(6):503–515. <https://doi.org/10.1056/NEJMoa2107519>.
341. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. *Lancet*. 2021;398(10300):583–598. [https://doi.org/10.1016/s0140-6736\(21\)01443-4](https://doi.org/10.1016/s0140-6736(21)01443-4).
342. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet*. 2021;398(10313):1811–1824. [https://doi.org/10.1016/s0140-6736\(21\)02188-7](https://doi.org/10.1016/s0140-6736(21)02188-7).
343. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. *JAMA*. 2022;327(6):534–545. <https://doi.org/10.1001/jama.2022.0078>.
344. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet*. 2021;398(10295):143–155. [https://doi.org/10.1016/s0140-6736\(21\)01324-6](https://doi.org/10.1016/s0140-6736(21)01324-6).
345. The effect of tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes (SURPASS-CVOT). ClinicalTrials.gov identifier: NCT04255433. <https://clinicaltrials.gov/study/NCT04255433>; Updated December 9, 2024. Accessed December 13, 2024.
346. Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes



- and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. *Am Heart J*. 2024;01/01/ 2024;267:1–11. <https://doi.org/10.1016/j.ahj.2023.09.007>.
347. Patoulas D, Papadopoulos C, Fragakis N, Doumas M. Updated meta-analysis assessing the cardiovascular efficacy of tirzepatide. *Am J Cardiol*. 2022;181:139–140. <https://doi.org/10.1016/j.amjcard.2022.07.003>.
  348. A study of tirzepatide (LY3298176) on the reduction on morbidity and mortality in adults with obesity (SURMOUNT-MMO). ClinicalTrials.gov identifier: NCT05556512. <https://clinicaltrials.gov/study/NCT05556512>; Updated December 6, 2024. Accessed December 13, 2024.
  349. Di Stefano R, Rindi LV, Baldini V, et al. Glucagon-like peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: a systematic review of clinical studies and pharmacovigilance reports. *Diabetes Metab Syndr*. 2025;19(4):103238. <https://doi.org/10.1016/j.dsx.2025.103238>.
  350. McIntyre RS, Mansur RB, Rosenblat JD, et al. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®). *J Affect Disord*. 2025;369:922–927. <https://doi.org/10.1016/j.jad.2024.10.062>.
  351. Valentino K, Teopiz KM, Cheung W, et al. The effect of glucagon-like peptide-1 receptor agonists on measures of suicidality: a systematic review. *J Psychiatr Res*. 2025;183:112–126. <https://doi.org/10.1016/j.jpsychires.2025.02.008>.
  352. Haws R, Brady S, Davis E, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. *Diabetes Obes Metab*. 2020;22(11):2133–2140. <https://doi.org/10.1111/dom.14133>.
  353. Ryan DH. Setmelanotide: what does it mean for clinical care of patients with obesity? *Lancet Diabetes Endocrinol*. 2020;8(12):933–935. [https://doi.org/10.1016/s2213-8587\(20\)30366-1](https://doi.org/10.1016/s2213-8587(20)30366-1).
  354. Markham A. Setmelanotide: first approval. *Drugs*. 2021;81(3):397–403. <https://doi.org/10.1007/s40265-021-01470-9>.
  355. Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. *Lancet Diabetes Endocrinol*. 2020;8(12):960–970. [https://doi.org/10.1016/s2213-8587\(20\)30364-8](https://doi.org/10.1016/s2213-8587(20)30364-8).
  356. Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. *Lancet Diabetes Endocrinol*. 2022;10(12):859–868. [https://doi.org/10.1016/s2213-8587\(22\)00277-7](https://doi.org/10.1016/s2213-8587(22)00277-7).
  357. Roth CL, Scimia C, Shoemaker AH, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. *Lancet Diabetes Endocrinol*. 2024;12(6):380–389. [https://doi.org/10.1016/s2213-8587\(24\)00087-1](https://doi.org/10.1016/s2213-8587(24)00087-1).
  358. Greenway FL, Aronne LJ, Raben A, et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. *Obesity (Silver Spring)*. 2019;27(2):205–216. <https://doi.org/10.1002/oby.22347>.
  359. Bays HE, Ard JD, O'Neil PM, et al. Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: prespecified and exploratory analysis of the Epitome capsule RESET study. *Obes Pillars*. 2025;13:100163. <https://doi.org/10.1016/j.obpill.2025.100163>.
  360. U.S. Food and Drug Administration. 510(k) premarket notification. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240544>. Accessed March 7, 2025.
  361. Hach M, Engelund DK, Mysling S, et al. Impact of manufacturing process and compounding on properties and quality of follow-on GLP-1 polypeptide drugs. *Pharm Res*. 2024;41(10):1991–2014. <https://doi.org/10.1007/s11095-024-03771-6>.
  362. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>. Accessed February 11, 2025.